INN_Name,BrandName,Phase,Applicants,Links,LigID,pdbID,Type,RoF,MW,LogP,TPSA,HBA,HBD,NRB,Indications,Targets,Kinase families,Canonical_Smiles_InChiKey,First_Approval,SC_Patent,Chirality,Synonyms,FDA approved,Melting points (°C)
Abemaciclib,Verzenio,4,Eli Lilly,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'6ZV',5l2s,1,1,506.3,4.9,75,8,1,7,"On September 28, 2017, the Food and Drug Administration approved abemaciclib (VERZENIO, Eli Lilly and Company) in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. In addition, abemaciclib was approved as monotherapy for women and men with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.","CDK4
CDK6",CMGC,"Smiles=CCN1CCN(CC1)Cc2ccc(nc2)Nc3ncc(c(n3)c4cc5c(c(c4)F)nc(n5C(C)C)C)F
InChiKey=UZWDCWONPYILKI-UHFFFAOYSA-N",2017,US-7855211-B2,Achiral Molecule,"Verzenio
Abemaciclib
LY-2835219",Y,
Abivertinib,nan,3,ACEA Biosciences,"ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,487.2,4.5,98.4,7,3,7,"AC0010 is an orally active, irreversible EGFR inhibitor that selectively targets mutated EGFRs, and was designed to overcome T790M-induced resistance in tumours [2]. It may also inhibit BTK, thus offering extended clinical utility [3]. We show the structure for the free base form of the compound.",nan,,"Smiles=CN1CCN(CC1)c2ccc(cc2F)Nc3nc4c(cc[nH]4)c(n3)Oc5cccc(c5)NC(=O)C=C
InChiKey=UOFYSRZSLXWIQB-UHFFFAOYSA-N",nan,nan,nan,"AC0010
Avitinib",,
Acalabrutinib,Calquence,4,Astrazeneca,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,465.2,3.3,118.5,7,2,4,Acalabrutinib is currently indicated for the treatment of adult patients with Mantle Cell Lymphoma (MCL) who have received at least one prior therapy,BTK,Tyr,"Smiles=CC#CC(=O)N1CCC[C@H]1c2nc(c3n2ccnc3N)c4ccc(cc4)C(=O)Nc5ccccn5
InChiKey=WDENQIQQYWYTPO-IBGZPJMESA-N",2017,US-9290504-B2,Single Stereoisomer,"Calquence
ACP-196
Acalabrutinib",Y,
Acalisib,nan,2,Gilead Sciences,"ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,401.1,3.4,101.4,7,2,4,nan,PIK3CA,Atypical,"Smiles=C[C@@H](c1nc2ccc(cc2c(=O)n1c3ccccc3)F)Nc4c5c(nc[nH]5)ncn4
InChiKey=DOCINCLJNAXZQF-LBPRGKRZSA-N",nan,nan,Single Stereoisomer,CAL-120,,
Acumapimod,nan,2,Mereo BioPharma,"ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,385.2,2.8,113.8,6,2,5,nan,"MAPK14
MAPK11
MAPK13
MAPK12",CMGC,"Smiles=Cc1ccc(cc1n2c(c(cn2)C(=O)c3cccc(c3)C#N)N)C(=O)NC4CC4
InChiKey=VGUSQKZDZHAAEE-UHFFFAOYSA-N",nan,nan,Single Stereoisomer,,,
Adavosertib,nan,2,Astrazeneca,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS",'8X7',5v5y 5vd0 5vdk,1,1,500.3,2.9,104.3,10,2,7,nan,WEE1,Other,"Smiles=CC(C)(c1cccc(n1)n2c3c(cnc(n3)Nc4ccc(cc4)N5CCN(CC5)C)c(=O)n2CC=C)O
InChiKey=BKWJAKQVGHWELA-UHFFFAOYSA-N",nan,nan,nan,"AZD-1775
MK-1775",,
Afatinib,Gilotrif,4,Boehringer Ingelheim,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'0WM',4g5j,1,0,485.2,4.4,88.6,7,2,8,Afatinib is a kinase inhibitor indicated for the first-line treatment of patient with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.,"EGFR
ERBB2
ERBB4",Tyr,"Smiles=CN(C)C/C=C/C(=O)Nc1cc2c(cc1O[C@H]3CCOC3)ncnc2Nc4ccc(c(c4)Cl)F
InChiKey=ULXXDDBFHOBEHA-CWDCEQMOSA-N",2013,US-6251912-B1,Single Stereoisomer,"Giotrif;Gilotrif
Afatinib
BIBW-2992",Y,
Afuresertib,nan,2,GlaxoSmithKline,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,426,3.9,72.9,5,2,6,nan,"AKT1
AKT2
AKT3",AGC,"Smiles=Cn1c(c(cn1)Cl)c2cc(sc2Cl)C(=O)N[C@@H](Cc3cccc(c3)F)CN
InChiKey=AFJRDFWMXUECEW-LBPRGKRZSA-N",nan,nan,Single Stereoisomer,"GSK2110183
Afuresertib
GSK2110183C",,
Alectinib,Alecensa,4,Hoffmann-La Roche,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'EMH',3aox 5xv7,1,0,482.3,4.8,72.4,5,1,3,"Alectinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",ALK,Tyr,"Smiles=CCc1cc2c(cc1N3CCC(CC3)N4CCOCC4)C(c5c(c6ccc(cc6[nH]5)C#N)C2=O)(C)C
InChiKey=KDGFLJKFZUIJMX-UHFFFAOYSA-N",2015,US-9126931-B2,Achiral Molecule,"Alectinib
CH-5424802
AF-802",Y,
Alisertib,nan,3,Millennium Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'A5B',5ia0,1,2,518.1,5.7,105.9,7,2,6,For the treatment of various forms of cancer.,AURKA,Other,"Smiles=COc1cccc(c1C2=NCc3cnc(nc3-c4c2cc(cc4)Cl)Nc5ccc(c(c5)OC)C(=O)O)F
InChiKey=ZLHFILGSQDJULK-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MLN-8237
Alisertib",,
Allitinib,nan,1,Allist Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC",NaN,NaN,nan,1,448.1,5.9,76.1,5,2,7,nan,"ERBB2
EGFR",Tyr,"Smiles=C=CC(=O)Nc1ccc2c(c1)c(ncn2)Nc3ccc(c(c3)Cl)OCc4cccc(c4)F
InChiKey=MVZGYPSXNDCANY-UHFFFAOYSA-N",nan,nan,nan,"AST-1306
ALL-3",,
Alpelisib,Piqray,4,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'1LT',4jps,nan,0,441.1,3.8,101.2,5,2,4,"On may 2019, FDA approved alpelisib to treat breast cancer",PIK3CA,Atypical,"Smiles=Cc1c(sc(n1)NC(=O)N2CCC[C@H]2C(=O)N)c3ccnc(c3)C(C)(C)C(F)(F)F
InChiKey=STUWGJZDJHPWGZ-LBPRGKRZSA-N",2019,nan,Single Stereoisomer,"NVP-BYL719
Alpelisib
BYL-719",Y,
Altiratinib,nan,1,Deciphera Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,510.2,5,109.4,5,3,8,nan,"MET
TEK
KDR
NTRK1",Tyr,"Smiles=c1cc(ccc1NC(=O)C2(CC2)C(=O)Nc3cc(c(cc3F)Oc4ccnc(c4)NC(=O)C5CC5)F)F
InChiKey=GNNDEPIMDAZHRQ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"DCC-2701
Altiratinib
DP-5164",,
Alvocidib,nan,3,Sanofi,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'CPB',1c8k 1e1y 3blr 3ebp 4o71,nan,0,401.1,3.3,94.1,6,3,2,"Investigated for use/treatment in esophageal cancer, leukemia (lymphoid), lung cancer, liver cancer, and lymphoma (unspecified).",nan,,"Smiles=CN1CC[C@@H]([C@@H](C1)O)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O
InChiKey=BIIVYFLTOXDAOV-YVEFUNNKSA-N",nan,nan,Single Stereoisomer,"L-86-8275
Flavopiridol
MDL-107826A
HL-275
HMR-1275
Alvocidib
NSC-649890
L-868275",,
Amcasertib,nan,2,Boston Biomedical,"ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS",NaN,NaN,nan,2,539.2,6,90.1,5,3,9,nan,PDGFRA,Tyr,"Smiles=CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)c4csc(n4)c5ccccc5)C
InChiKey=QDWKGEFGLQMDAM-ULJHMMPZSA-N",nan,nan,Achiral Molecule,"BBI-503
Amcasertib",,
Amuvatinib,nan,2,Supergen,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,447.1,3.3,75.9,7,1,3,"Amuvatinib is a selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical comp\nonent of double-stranded DNA repair in cancer cells.","KIT
MET
RET
FLT3
PDGFRB",Tyr,"Smiles=c1ccc2c(c1)c3c(o2)c(ncn3)N4CCN(CC4)C(=S)NCc5ccc6c(c5)OCO6
InChiKey=FOFDIMHVKGYHRU-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MP-470
HPK56
Amuvatinib
HPK-56",,
Anlotinib,nan,4,Advenchen Laboratories,"ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,407.2,4.8,82.4,5,2,6,"Anlotinib (AL3818) is a non-selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor type 2 (VEGFR-2, FLT1) and type 3 (VEGFR-3, FLT4). It is being investigated for antineoplastic and anti-angiogenic potential. The dihydrochloride has PubChem CID: 57380530. Preparation and crystallisation of AL3818 is described in patent WO2016179123.","KDR
FLT4",Tyr,"Smiles=Cc1cc2c([nH]1)ccc(c2F)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC
InChiKey=KSMZEXLVHXZPEF-UHFFFAOYSA-N",nan,nan,nan,"ALTN

APCII
AL3818
ATC I
FU KE WEI
APC I
ATCII
ANLOTINIB",N,
Apatinib,nan,4,Bukwang Pharmaceutical,"ChemSpider
PubChem
Guide to Pharmacology
ZINC",NaN,NaN,nan,1,397.2,5.1,90.7,5,2,5,"Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. The free-base form is also known as Rivoceranib. Apatinib selectively binds to and inhibits vascular endothelial growth factor receptor 2, which may inhibit VEGF-stimulated endothelial cell migration and proliferation and decrease tumor microvessel density. In addition, this agent mildly inhibits c-Kit and c-SRC tyrosine kinases.",KDR,Tyr,"Smiles=N#CC1(CCCC1)c1ccc(cc1)NC(=O)c1cccnc1Nc1cnccc1C
InChiKey=MGZNERAVOCFMCU-UHFFFAOYSA-N",2014,nan,nan,"NO.
STUDY DRUG
5-FLUOROURACIL
VP-16
ALBUMIN PACLITAXEL
AITAN
DOCETAXEL
EGAFUR
EMOZOLOMIDE（TMZ）
PLATINU
NAVELBINE+AITAN
PEMETREXED
H20140103
S1
ARGET THERAPY
SPA
YN968D1
CARBOPLATIN
ARM A
PACLITAXOL
XELOX
APATINIB GROUP
S-1
ATAN
AI TAN
APATINIB
REATMENT GROUP
CAPECITABINE
YEW
APATINIB MESYLATE
ESYLATE APATINIB
APATINIB TABLETS
OXALIPLATIN
YN968D1,(AITAN®",N,
Apitolisib,nan,2,Hoffmann-La Roche,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'980',3tl5,nan,1,498.2,0.9,133.8,11,2,5,nan,"PIK3CA
MTOR",Atypical,"Smiles=Cc1c(sc2c1nc(nc2N3CCOCC3)c4cnc(nc4)N)CN5CCN(CC5)C(=O)[C@H](C)O
InChiKey=YOVVNQKCSKSHKT-HNNXBMFYSA-N",nan,nan,Single Stereoisomer,"GDC-0980.1
RG-7422
G-038390.1
GDC-0980
Apitolisib
G-038390",,
Asciminib,nan,3,Novartis,"ChemSpider
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS",'AY7',5mo4,nan,0,449.1,3.5,103.4,6,3,6,nan,nan,,"Smiles=c1cc(ccc1NC(=O)c2cc(c(nc2)N3CC[C@H](C3)O)c4ccn[nH]4)OC(F)(F)Cl
InChiKey=VOVZXURTCKPRDQ-CQSZACIVSA-N",nan,nan,nan,ASCIMINIB,,
Avapritinib,nan,3,Blueprint Medicines,"ChemSpider
PubChem
DrugBank
Guide to Pharmacology
FDA SRS",NaN,NaN,nan,0,498.2,2.6,106.3,10,1,5,nan,nan,,"Smiles=C[C@](c1ccc(cc1)F)(c2cnc(nc2)N3CCN(CC3)c4c5cc(cn5ncn4)c6cnn(c6)C)N
InChiKey=DWYRIWUZIJHQKQ-SANMLTNESA-N",nan,nan,nan,BLU-285,,
Axitinib,Inlyta,4,Pfizer,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'AXI',4ag8 4agc 4twp 4wa9,2,0,386.1,4.6,70.7,4,2,5,Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.,"FLT1
KDR
FLT4",Tyr,"Smiles=CNC(=O)c1ccccc1Sc2ccc3c(c2)[nH]nc3/C=C/c4ccccn4
InChiKey=RITAVMQDGBJQJZ-FMIVXFBMSA-N",2012,US-6534524-B1,Achiral Molecule,"Inlyta
AG-13736
Axitinib
AG-013736",Y,
Bafetinib,nan,2,Innovive Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'406',2e2b,2,2,576.3,5.4,99.2,8,2,8,nan,"LYN
ABL1",Tyr,"Smiles=Cc1ccc(cc1Nc2nccc(n2)c3cncnc3)NC(=O)c4ccc(c(c4)C(F)(F)F)CN5CC[C@@H](C5)N(C)C
InChiKey=ZGBAJMQHJDFTQJ-DEOSSOPVSA-N",nan,nan,Single Stereoisomer,"CNS-9
Bafetinib
NS-187
INNO-406",,
Balamapimod,nan,1,Wyeth,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,2,573.2,6.5,82.2,9,1,7,nan,"RAF1
MAP2K1
MAP2K2","TKL
STE","Smiles=Cn1ccnc1Sc2ccc(cc2Cl)Nc3c4cc(c(cc4ncc3C#N)N5CCC(CC5)N6CCCC6)OC
InChiKey=CVAKNHIXTWLGJO-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MKI-833
Balamapimod",,
Barasertib,nan,3,Astrazeneca,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,587.2,3.6,174.8,9,5,15,nan,AURKB,Other,"Smiles=CCN(CCCOc1ccc2c(c1)ncnc2Nc3cc(n[nH]3)CC(=O)Nc4cccc(c4)F)CCOP(=O)(O)O
InChiKey=GBJVVSCPOBPEIT-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Barasertib
AZD-1152",,
Baricitinib,Olumiant,4,Eli Lilly,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'3JW',4w9x,1,0,371.1,1.1,120.6,7,1,5,"Indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs as monotherapy or in combination with methotrexate.","JAK1
JAK2",Tyr,"Smiles=CCS(=O)(=O)N1CC(C1)(CC#N)n2cc(cn2)c3c4cc[nH]c4ncn3
InChiKey=XUZMWHLSFXCVMG-UHFFFAOYSA-N",2017,nan,Achiral Molecule,"Baricitinib
LY-3009104
INCB-28050
INCB-028050",Y,
Bemcentinib,nan,2,BerGenBio,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,506.3,4.9,97.8,8,2,4,nan,AXL,Tyr,"Smiles=c1ccc-2c(c1)CCCc3c2nnc(c3)n4c(nc(n4)Nc5ccc6c(c5)CC[C@H](CC6)N7CCCC7)N
InChiKey=KXMZDGSRSGHMMK-VWLOTQADSA-N",nan,nan,nan,"BGB324; KEYTRUDA

BEMCENTINIB",,
Bentamapimod,nan,2,PregLem,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology",NaN,NaN,nan,0,457.2,4.2,84.2,8,0,7,nan,"MAPK8
MAPK9",CMGC,"Smiles=N#CC(c1nc2ccccc2s1)c5nc(OCc3ccc(cc3)CN4CCOCC4)ncc5
InChiKey=XCPPIJCBCWUBNT-UHFFFAOYSA-N",nan,nan,Racemic Mixture,"PGL-5001
Bentamapimod
AS-602801",,
Berzosertib,nan,2,Vertex Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,463.2,3.9,124,8,2,7,nan,nan,,"Smiles=CC(C)S(=O)(=O)c1ccc(cc1)c2cnc(c(n2)c3cc(no3)c4ccc(cc4)CNC)N
InChiKey=JZCWLJDSIRUGIN-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"VX-970
Berzosertib",,
Bimiralisib,nan,2,Piqur Therapeutics,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS",'A3W',5oq4,nan,0,411.2,1,103.2,8,2,3,"Bimiralisib (PQR309) is a novel dual inhibitor of phosphoinositol 3-kinase (PI3K) and mechanistic target of rapamycin (mTOR) kinases, with expected utility as an anti-cancer agent.",nan,,"Smiles=c1c(c(c[nH]c1=N)c2nc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F
InChiKey=ADGGYDAFIHSYFI-UHFFFAOYSA-N",nan,nan,nan,"PQR309
BIMIRALISIB",,
Binimetinib,Mektovi,4,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,440,3,88.4,6,3,6,"On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",MAP2K1,STE,"Smiles=Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3F)Br)C(=O)NOCCO
InChiKey=ACWZRVQXLIRSDF-UHFFFAOYSA-N",2018,nan,Achiral Molecule,"ARRY-162
NVP-MEK162
Binimetinib
MEK-162
ARRY-438162",Y,
Bosutinib,Bosulif,4,Wyeth,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'DB8',3soa 3ue4 4mxo 4mxx 4mxy 4mxz 4qmn 5ajq 5i9x 5vc3 5vcy 6fdy 6op9,1,2,529.2,5.2,82.9,8,1,9,"Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients.","BCR
ABL1
LYN
HCK
SRC
CDK2
MAP2K1
MAP2K2
MAP3K2
CAMK2G","Atypical
Tyr
STE
CAMK
CMGC","Smiles=CN1CCN(CC1)CCCOc2cc3c(cc2OC)c(c(cn3)C#N)Nc4cc(c(cc4Cl)Cl)OC
InChiKey=UBPYILGKFZZVDX-UHFFFAOYSA-N",2012,US-6002008-A,Achiral Molecule,"Bosulif
Bosutinib Monohydrate
Bosutinib
SKI-606",Y,
Brigatinib,Alunbrig,4,Ariad Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
ZINC
FDA SRS
BindingDB",'6GY',6mx8,1,2,583.3,5.1,85.9,9,2,8,"The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target. The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules. The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival. Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.","ALK
EGFR",Tyr,"Smiles=CN1CCN(CC1)C2CCN(CC2)c3ccc(c(c3)OC)Nc4ncc(c(n4)Nc5ccccc5P(=O)(C)C)Cl
InChiKey=AILRADAXUVEEIR-UHFFFAOYSA-N",2017,US-9012462-B2,Achiral Molecule,"Alunbrig
AP-26113
Brigatinib",Y,
Brivanib,nan,3,Bristol Myers Squibb,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,370.1,3.5,84.7,6,2,5,nan,KDR,Tyr,"Smiles=Cc1cc2c([nH]1)ccc(c2F)Oc3c4c(c(cn4ncn3)OC[C@@H](C)O)C
InChiKey=WCWUXEGQKLTGDX-LLVKDONJSA-N",nan,nan,Single Stereoisomer,"Brivanib
BMS-540215",,
Buparlisib,nan,3,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'SD5',3sd5 5m7e,1,0,410.2,1.8,89.6,8,1,3,nan,PIK3CA,Atypical,"Smiles=c1c(c(cnc1N)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F
InChiKey=CWHUFRVAEUJCEF-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"NVP-BKM120
BKM-120
Buparlisib
BKM120-NX",,
Cabozantinib,Cabometyx;Cometriq,4,Exelixis,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,2,2,501.2,5.5,98.8,6,2,8,For the treatment of metastatic medullary thyroid cancer and for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.,"MET
KDR
RET",Tyr,"Smiles=COc1cc2c(ccnc2cc1OC)Oc3ccc(cc3)NC(=O)C4(CC4)C(=O)Nc5ccc(cc5)F
InChiKey=ONIQOQHATWINJY-UHFFFAOYSA-N",2012,US-7579473-B2,Achiral Molecule,"Cabometyx;Cometriq
XL-184
Cabozantinib
BMS-907351",Y,
Canertinib,nan,3,Pfizer,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,485.2,4.4,88.6,7,2,9,Investigated for use/treatment in breast cancer and lung cancer.,EGFR,Tyr,"Smiles=C=CC(=O)Nc1cc2c(cc1OCCCN3CCOCC3)ncnc2Nc4ccc(c(c4)Cl)F
InChiKey=OMZCMEYTWSXEPZ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"CI-1033
Canertinib",,
Capivasertib,nan,2,Astrazeneca,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'0XZ',4gv1,nan,0,428.2,2.1,120.2,6,4,6,nan,AKT1,AGC,"Smiles=c1cc(ccc1[C@H](CCO)NC(=O)C2(CCN(CC2)c3c4cc[nH]c4ncn3)N)Cl
InChiKey=JDUBGYFRJFOXQC-KRWDZBQOSA-N",nan,nan,nan,AZD-5363,,
Capmatinib,nan,3,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,412.1,3.4,85.1,6,1,4,nan,MET,Tyr,"Smiles=CNC(=O)c1ccc(cc1F)c2cnc3ncc(n3n2)Cc4ccc5c(c4)cccn5
InChiKey=LIOLIMKSCNQPLV-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"INC280
Capmatinib
INCB-28060
NVP-INC280
NYP-INC280-NX
INC-280",,
Cediranib,Recentin,3,Astrazeneca,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,450.2,5.2,72.5,6,1,8,"For the treatment of liver cancer, advanced non-small cell lung cancer (NSCLC), advanced colorectal cancer (CRC) and other solid tumors.",KDR,Tyr,"Smiles=Cc1cc2c([nH]1)ccc(c2F)Oc3c4cc(c(cc4ncn3)OCCCN5CCCC5)OC
InChiKey=XXJWYDDUDKYVKI-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Recentin
ZD-2171
AZD-2171
Cediranib",,
Cenisertib,nan,1,EMD Serono,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,451.2,2.5,99.4,7,3,6,nan,"AURKA
AURKB
AURKC",Other,"Smiles=Cc1cc(ccc1N2CCN(CC2)C)Nc3ncc(c(n3)N[C@@H]4[C@@H]5C[C@H]([C@@H]4C(=O)N)C=C5)F
InChiKey=KSOVGRCOLZZTPF-QMKUDKLTSA-N",nan,nan,Racemic Mixture,"R-763
AS-703569",,
Ceralasertib,nan,2,Astrazeneca,"ChemSpider
PubChem",NaN,NaN,nan,0,412.2,2.9,107.8,7,2,4,"Ceralasertib, also known as AZD6738, is an orally available morpholino-pyrimidine-based inhibitor of ataxia telangiectasia and rad3 related (ATR) kinase, with potential antineoplastic activity. Upon oral administration, ATR kinase inhibitor Ceralasertib selectively inhibits ATR activity by blocking the downstream phosphorylation of the serine/threonine protein kinase CHK1. This prevents ATR-mediated signaling, and results in the inhibition of DNA damage checkpoint activation, disruption of DNA damage repair, and the induction of tumor cell apoptosis.",nan,,"Smiles=CC1COCCN1c2cc(nc(n2)c3cncc4c3cc[nH]4)C5(CC5)S(=N)(=O)C
InChiKey=DTTJKLNXNZAVSM-UHFFFAOYSA-N",nan,nan,nan,AZD6738,,
Cerdulatinib,nan,2.5,Portola pharmaceuticals,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,445.2,1.4,133.6,8,3,8,nan,"JAK1
SYK",Tyr,"Smiles=CCS(=O)(=O)N1CCN(CC1)c2ccc(cc2)Nc3ncc(c(n3)NC4CC4)C(=O)N
InChiKey=BGLPECHZZQDNCD-UHFFFAOYSA-N",nan,nan,Single Stereoisomer,PRT-062070,,
Ceritinib,Zykadia,4,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'4MK',4mkc,1,2,557.2,6.4,105.2,8,3,9,Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.,ALK,Tyr,"Smiles=Cc1cc(c(cc1C2CCNCC2)OC(C)C)Nc3ncc(c(n3)Nc4ccccc4S(=O)(=O)C(C)C)Cl
InChiKey=VERWOWGGCGHDQE-UHFFFAOYSA-N",2014,US-7153964-B2,Achiral Molecule,"Zykadia
Ceritinib
NVP-LDK378-NX",Y,
Cobimetinib,Cotellic,4,Hoffmann-La Roche,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'EUI',4an2 4lmn,3,1,531.1,3.8,64.6,4,3,4,"For the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. Cobimetinib is used in combination with vemurafenib, a BRAF inhibitor.",MAP2K1,STE,"Smiles=c1c(cc(c(c1)Nc2c(c(ccc2C(=O)N3C[C@@](C3)(O)[C@H]4NCCCC4)F)F)F)I
InChiKey=BSMCAPRUBJMWDF-KRWDZBQOSA-N",2015,US-7803839-B2,Single Stereoisomer,"Cotellic
RG-7421
GDC-0973
RG-7420
XL-518
Cobimetinib",Y,
Copanlisib,Aliqopa,4,Bayer,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'6E2',5g2n,1,1,480.2,0.7,139.8,11,2,7,Indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.,"PIK3CA
PIK3CB",Atypical,"Smiles=COc1c(ccc2c1N=C(N3C2=NCC3)NC(=O)c4cnc(nc4)N)OCCCN5CCOCC5
InChiKey=PZBCKZWLPGJMAO-UHFFFAOYSA-N",2017,US-7511041-B2,Achiral Molecule,"Copanlisib
BAY 80-6946
BAY-80-6946",Y,
Crenolanib,nan,3,Arog Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'6T2',5lby 6bqp,1,0,443.2,3.9,78.4,7,1,5,nan,"FLT3
PDGFRA
PDGFRB",Tyr,"Smiles=CC1(COC1)COc2ccc3c(c2)ncn3c4ccc5cccc(c5n4)N6CCC(CC6)N
InChiKey=DYNHJHQFHQTFTP-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"CP-868596
ARO-002
Crenolanib",,
Crizotinib,Xalkori,4,Pfizer,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'VGH',2wgj 2xp2 2yfx 3zbf 4anq 4ans 4c9w 5aaa 5aab 5aac 6imz,1,1,449.1,5,78,6,2,5,Crizotinib is used for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic-lymphoma kinase (ALK)-positive as detected by a FDA-approved test.,"ALK
MET",Tyr,"Smiles=C[C@H](c1c(ccc(c1Cl)F)Cl)Oc2cc(cnc2N)c3cnn(c3)C4CCNCC4
InChiKey=KTEIFNKAUNYNJU-GFCCVEGCSA-N",2011,US-7230098-B2,Single Stereoisomer,"Xalkori
Crizotinib
PF-2341066",Y,
Dabrafenib,Tafinlar,4,GlaxoSmithKline,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'P06',4xv2 5csw 5hie,1.5,2,519.1,5.4,110.9,7,2,5,Dabrafenib is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.,"BRAF
RAF1
SIK1
NEK11
LIMK1","NEK
TKL
CAMK","Smiles=CC(C)(C)c1nc(c(s1)c2ccnc(n2)N)c3cccc(c3F)NS(=O)(=O)c4c(cccc4F)F
InChiKey=BFSMGDJOXZAERB-UHFFFAOYSA-N",2013,US-7994185-B2,Achiral Molecule,"Tafinlar
GSK2118436A
Dabrafenib",Y,
Dacomitinib,Vizimpro,4,Pfizer,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'1C9',4i23 4i24,1,1,469.2,5.2,79.4,6,2,7,"On october 27, 2018, the FDA approved dacomitinib to treat metastatic non-small-cell lung cancer",EGFR,Tyr,"Smiles=COc1cc2c(cc1NC(=O)/C=C/CN3CCCCC3)c(ncn2)Nc4ccc(c(c4)Cl)F
InChiKey=LVXJQMNHJWSHET-AATRIKPKSA-N",2018,nan,Achiral Molecule,"Dacomitinib
PF-00299804",Y,184-187
Dactolisib,nan,2,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,469.2,5.9,76.5,6,0,3,nan,"PIK3CA
PIK3CB
PIK3CG
PIK3CD
MTOR",Atypical,"Smiles=CC(C)(C#N)c1ccc(cc1)n2c3c4cc(ccc4ncc3n(c2=O)C)c5cc6ccccc6nc5
InChiKey=JOGKUKXHTYWRGZ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Dactolisib
NVP-BEZ235-NX
BEZ-235
NVP-BEZ235",,
Danusertib,nan,2,Nerviano Medical Sciences,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'627',2j50 2v7a 4qo9 5i9z,1,0,474.2,2.6,93.8,6,2,6,nan,"AURKA
AURKB
AURKC",Other,"Smiles=CN1CCN(CC1)c2ccc(cc2)C(=O)Nc3c4c([nH]n3)CN(C4)C(=O)[C@@H](c5ccccc5)OC
InChiKey=XKFTZKGMDDZMJI-HSZRJFAPSA-N",nan,nan,Single Stereoisomer,"Danusertib
PHA-739358",,
Dasatinib,Sprycel,4,Bristol Myers Squibb,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'1N1',2gqg 2y6o 2zva 3g5d 3k54 3lfa 3oct 3oht 3qlg 3sxr 4qms 4xey 4xli 5bvw 5h2u 5i9y 5owr 5vcv 6bsd 6fnm,1,0,487.2,3.3,106.5,9,3,7,"For the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy. Also indicated for the treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy.","ABL1
SRC
EPHA2
LCK
YES1
KIT
PDGFRB
ABL2
FYN",Tyr,"Smiles=Cc1cccc(c1NC(=O)c2cnc(s2)Nc3cc(nc(n3)C)N4CCN(CC4)CCO)Cl
InChiKey=ZBNZXTGUTAYRHI-UHFFFAOYSA-N",2006,US-6596746-B1,Achiral Molecule,"Sprycel;Dasatinib
BMS-354825-03
BMS-354825
Dasatinib",Y,280-286
Decernotinib,nan,2,Vertex Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'VJK',4yti,1,0,392.2,3.3,95.6,5,3,6,nan,JAK3,Tyr,"Smiles=CC[C@](C)(C(=O)NCC(F)(F)F)Nc1ccnc(n1)c2c[nH]c3c2cccn3
InChiKey=ASUGUQWIHMTFJL-QGZVFWFLSA-N",nan,nan,Single Stereoisomer,"VRT-831509
Adelatinib
VX-509
Decernotinib",,
Defactinib,nan,2,Verastem,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS",'7KD',5mah,1,1,510.1,2.4,142.1,9,3,8,nan,"PTK2
PTK2B",Tyr,"Smiles=CNC(=O)c1ccc(cc1)Nc2ncc(c(n2)NCc3c(nccn3)N(C)S(=O)(=O)C)C(F)(F)F
InChiKey=FWLMVFUGMHIOAA-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"PF-04554878
VS-6063
Defactinib",,
Derazantinib,nan,1.5,ArQule,"ChemSpider
PubChem
DrugBank
Guide to Pharmacology
FDA SRS",NaN,NaN,nan,1,468.2,5.5,59.1,5,2,9,"Derazantinib (ARQ087) is an orally bioavailable, non-selective FGFR inhibitor being investigated for antineoplastic activity.",nan,,"Smiles=COCCNCCc1cccc(c1)Nc2ncc3c(n2)-c4ccccc4[C@@H](C3)c5ccccc5F
InChiKey=KPJDVVCDVBFRMU-AREMUKBSSA-N",nan,nan,nan,,,
Dezapelisib,nan,0,Incyte Corporation,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,421.1,3.7,100.9,8,2,4,nan,nan,,"Smiles=Cc1csc2n1c(=O)c(c(n2)[C@H](C)Nc3c4c([nH]cn4)ncn3)c5cccc(c5)F
InChiKey=RSIWALKZYXPAGW-NSHDSACASA-N",nan,nan,Single Stereoisomer,"INCB040093
Dezapelisib",,
Dilmapimod,nan,2,GlaxoSmithKline,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,456.1,2.9,100.3,7,3,6,"Dilmapimod has been used in trials studying the treatment and diagnostic of Nerve Trauma, Inflammation, Pain, Neuropathic, Arthritis, Rheumatoid, and Coronary Heart Disease, among others.","MAPK14
MAPK11
MAPK13
MAPK12",CMGC,"Smiles=Cc1cc(ccc1c2c3ccc(=O)n(c3nc(n2)NC(CO)CO)c4c(cccc4F)F)F
InChiKey=ORVNHOYNEHYKJG-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Dilmapimod
GW681323
SB-681323",,
Dinaciclib,nan,3,Schering-Plough,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,396.2,2.3,92.6,7,2,7,nan,"CDK4
CDK6
BRDT","(*)
CMGC","Smiles=CCc1cnn2c1nc(cc2NCc3ccc[n+](c3)[O-])N4CCCC[C@H]4CCO
InChiKey=PIMQWRZWLQKKBJ-SFHVURJKSA-N",nan,nan,Single Stereoisomer,"MK-7965
SCH-727965
Dinaciclib",,
Doramapimod,nan,2,Boehringer Ingelheim,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'B96',1kv2 3fzs 3npc 4jvg 4twn 5n66 6gtt,2,2,527.3,6,80.7,6,2,7,nan,MAPK14,CMGC,"Smiles=Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)Nc3ccc(c4c3cccc4)OCCN5CCOCC5
InChiKey=MVCOAUNKQVWQHZ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Doramapimod
BIRB-796",,
Dovitinib,nan,3,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
ZINC
FDA SRS
BindingDB",'38O',4tyi 5a46 5am6 5am7 5owq,1,0,392.2,2.5,94,5,3,2,nan,"FGFR3
VEGFA
FGFR1
PDGFRA
KIT
CSF1R","(*)
Tyr","Smiles=CN1CCN(CC1)c2ccc3c(c2)[nH]c(n3)c4c(c5c(cccc5F)[nH]c4=O)N
InChiKey=PIQCTGMSNWUMAF-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"GFKI-258
TKI-258
CHIR-258
NVP-TKI258
Dovitinib",,
Duvelisib,Copiktra,4,Infinity Pharmacueticals,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,416.1,4.5,88.5,6,2,4,"On october 27, 2018, the FDA approved duvelisib to treat relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma","PIK3CD
PIK3CG",Atypical,"Smiles=C[C@@H](c1cc2cccc(c2c(=O)n1c3ccccc3)Cl)Nc4c5c([nH]cn5)ncn4
InChiKey=SJVQHLPISAIATJ-ZDUSSCGKSA-N",2018,nan,Single Stereoisomer,"INK-1197
INK-1147
IPI-145
Duvelisib",Y,>190
Encorafenib,Braftovi,4,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,539.2,3.9,140.1,9,3,9,"On June 27, 2018, the Food and Drug Administration approved encorafenib and binimetinib in combination patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",BRAF,TKL,"Smiles=C[C@@H](CNc1nccc(n1)c2cn(nc2c3cc(cc(c3F)NS(=O)(=O)C)Cl)C(C)C)NC(=O)OC
InChiKey=CMJCXYNUCSMDBY-ZDUSSCGKSA-N",2018,nan,Single Stereoisomer,"NVP-LGX818-NXA
LGX-818
Encorafenib
NVP-LGX818",Y,
Ensartinib,nan,3,Xcovery,"ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,560.2,4.7,122.5,7,3,6,nan,ALK,Tyr,"Smiles=C[C@@H]1CN(C[C@@H](N1)C)C(=O)c2ccc(cc2)NC(=O)c3cc(c(nn3)N)O[C@H](C)c4c(ccc(c4Cl)F)Cl
InChiKey=GLYMPHUVMRFTFV-QLFBSQMISA-N",nan,nan,nan,"X-396
X396
X-396 CAPSULES
ENSARTINIB",,
Entospletinib,nan,2,Gilead Sciences,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'CG9',4puz,1,0,411.2,3.9,83.4,7,2,4,nan,SYK,Tyr,"Smiles=c1cc(ccc1Nc2c3nccn3cc(n2)c4ccc5cn[nH]c5c4)N6CCOCC6
InChiKey=XSMSNFMDVXXHGJ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"GS-9973
Entospletinib",,
Entrectinib,Rozlytrek,4,Ignyta,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'YMX',5fto 5kvt,1,2,560.3,5,85.5,6,3,7,"On august 2019, FDA approved entrectinib to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive and to treat adult and pediatric patients 12 years of age and older with solid tumors","NTRK1
NTRK2
NTRK3
ROS1
ALK",Tyr,"Smiles=CN1CCN(CC1)c2ccc(c(c2)NC3CCOCC3)C(=O)Nc4c5cc(ccc5[nH]n4)Cc6cc(cc(c6)F)F
InChiKey=HAYYBYPASCDWEQ-UHFFFAOYSA-N",2019,nan,Achiral Molecule,"Entrectinib
RXDX-101
NMS-E628",Y,
Enzastaurin,nan,3,Eli Lilly,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,515.2,4.9,72.2,6,1,5,nan,nan,,"Smiles=Cn1cc(c2c1cccc2)C3=C(C(=O)NC3=O)c4cn(c5c4cccc5)C6CCN(CC6)Cc7ccccn7
InChiKey=AXRCEOKUDYDWLF-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"LY-317615
Enzastaurin",,
Erdafitinib,Balversa,4,Janssen,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS",'5SF',5ew8,1,0,446.2,4.2,77.3,8,1,9,"On april 2019, FDA approved erdafitinib to treat adult patients with locally advanced or metastatic bladder cancer",FGFR1,Tyr,"Smiles=CC(C)NCCN(c1ccc2c(c1)nc(cn2)c3cnn(c3)C)c4cc(cc(c4)OC)OC
InChiKey=OLAHOMJCDNXHFI-UHFFFAOYSA-N",2019,nan,Achiral Molecule,"Erdafitinib
JNJ-42756493",Y,
Erlotinib,Tarceva,4,Osi Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'AQ4',1m17 4hjo 6dwn,1.5,0,393.2,3.4,74.7,7,1,10,"For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.","EGFR
NR1I2","(*)
Tyr","Smiles=COCCOc1cc2c(cc1OCCOC)ncnc2Nc3cccc(c3)C#C
InChiKey=AAKJLRGGTJKAMG-UHFFFAOYSA-N",2004,US-5747498-A,Achiral Molecule,"Tarceva
Erlotinib
OSI-774
RG-1415
CP-358774
R-1415
Ro-508231",Y,
Evobrutinib,nan,2,Merck,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'MZJ',6omu,nan,0,429.2,4.4,93.4,6,2,7,nan,BTK,Tyr,"Smiles=C=CC(=O)N1CCC(CC1)CNc2c(c(ncn2)N)c3ccc(cc3)Oc4ccccc4
InChiKey=QUIWHXQETADMGN-UHFFFAOYSA-N",nan,nan,nan,EVOBRUTINIB,,
Famitinib,nan,3,Jiangsu Hengrui Medicine,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,410.2,3.3,68.4,3,2,6,nan,"KIT
KDR
FLT4
PDGFRA
PDGFRB
FLT1
FLT3",Tyr,"Smiles=CCN(CC)CCN1CCc2c(c(c([nH]2)/C=C\3/c4cc(ccc4NC3=O)F)C)C1=O
InChiKey=GKEYKDOLBLYGRB-LGMDPLHJSA-N",nan,nan,nan,SHR-1020,,
Fasudil,nan,4,Asahi Kasei Pharma Corp,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'M77',1q8w 2esm 2f2u 2gni 3tku 5lcp 5nw8 5o0e 5ok3 5vef 6em2 6emb 6ers 6erw 6i2a 6i2c,nan,0,291.1,1.2,62.3,4,1,2,Fasudil is a potent inhibitor of the Rho-kinases ROCK1 and ROCK2.,nan,,"Smiles=c1cc2cnccc2c(c1)S(=O)(=O)N3CCCNCC3
InChiKey=NGOGFTYYXHNFQH-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"HA-1077
Fasudil
ZK-258594
AT-877",N,
Fedratinib,Inrebic,4,Sanofi,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'2TA',4ogj 4ps5,nan,1,524.3,4.8,108.5,8,3,10,"On august 2019, FDA approved fedratinib to treat adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis","JAK2
FLT3
BRD4","(*)
Tyr","Smiles=Cc1cnc(nc1Nc2cccc(c2)S(=O)(=O)NC(C)(C)C)Nc3ccc(cc3)OCCN4CCCC4
InChiKey=JOOXLOJCABQBSG-UHFFFAOYSA-N",2019,nan,Achiral Molecule,"SAR-302503
Fedratinib
TG101348
TG-101348",Y,
Filgotinib,nan,3,Galapagos,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'2HB',4p7e 5ut5,1,0,425.2,2,96.7,7,1,5,nan,JAK1,Tyr,"Smiles=c1cc(n2c(c1)nc(n2)NC(=O)C3CC3)c4ccc(cc4)CN5CCS(=O)(=O)CC5
InChiKey=RIJLVEAXPNLDTC-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"G-146034
GLPG-0634
Filgotinib",,
Flumatinib,nan,3,Jiangsu Hengrui Medicine,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,2,562.2,5,99.2,8,2,7,nan,"BCR
ABL1
PDGFRB
KIT","Atypical
Tyr","Smiles=Cc1c(cc(cn1)NC(=O)c2ccc(c(c2)C(F)(F)F)CN3CCN(CC3)C)Nc4nccc(n4)c5cccnc5
InChiKey=BJCJYEYYYGBROF-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"HHGV-678
Flumatinib",,
Foretinib,nan,2,GlaxoSmithKline,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'88Z',3lq8 5ia4 6i2y 6sd9 6sdc,2,2,632.2,5.8,111.2,8,2,12,nan,"MET
KDR",Tyr,"Smiles=COc1cc2c(ccnc2cc1OCCCN3CCOCC3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
InChiKey=CXQHYVUVSFXTMY-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"EXEL-2880
Foretinib
GSK1363089G
GSK1363089
GSK-1363089
XL-880
GSK089",,
Fostamatinib,Tavalisse,4,Rigel Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'2RC',4o75,nan,2,580.1,3.1,186.7,12,4,10,Indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who have had an insufficient response to a previous treatment,SYK,Tyr,"Smiles=CC1(C(=O)N(c2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)COP(=O)(O)O)C
InChiKey=GKDRMWXFWHEQQT-UHFFFAOYSA-N",2018,nan,Achiral Molecule,"R-935788
R-788 Free acid
R-935788 Free acid
Fostamatinib
R-788",Y,
Fruquintinib,nan,3,Hutchison MediPharma,"ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,393.1,3.9,95.7,7,1,5,nan,"FLT1
KDR
FLT4",Tyr,"Smiles=Cc1c(c2ccc(cc2o1)Oc3c4cc(c(cc4ncn3)OC)OC)C(=O)NC
InChiKey=BALLNEJQLSTPIO-UHFFFAOYSA-N",nan,nan,Single Stereoisomer,"HMP-013

HMPL-013",,
Galunisertib,nan,2,Eli Lilly,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,369.2,3.5,86.7,5,1,3,nan,TGFBR1,TKL,"Smiles=Cc1cccc(n1)c2c(c3n(n2)CCC3)c4ccnc5c4cc(cc5)C(=O)N
InChiKey=IVRXNBXKWIJUQB-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Galunisertib
LY-2157299",,
Gandotinib,nan,2,Eli Lilly,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,469.2,4,83.4,7,2,6,nan,JAK2,Tyr,"Smiles=Cc1cc(n[nH]1)Nc2cc(c3nc(c(n3n2)Cc4ccc(cc4F)Cl)C)CN5CCOCC5
InChiKey=SQSZANZGUXWJEA-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"LY-2784544
Gandotinib",,
Gedatolisib,nan,2,Pfizer,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,615.3,3,128.3,10,2,7,nan,"PIK3CA
PIK3CB
PIK3CG
PIK3CD
MTOR",Atypical,"Smiles=CN(C)C1CCN(CC1)C(=O)c2ccc(cc2)NC(=O)Nc3ccc(cc3)c4nc(nc(n4)N5CCOCC5)N6CCOCC6
InChiKey=DWZAEMINVBZMHQ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"PKI-587
Gedatolisib
PF-05212384",,
Gefitinib,Iressa,4,Astrazeneca,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'IRE',2ito 2ity 2itz 3ug2 4i22 4wkq 5y7z 5y80,1.5,0,446.2,4.3,68.7,7,1,8,For the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of either platinum-based or docetaxel chemotherapies.,EGFR,Tyr,"Smiles=COc1cc2c(cc1OCCCN3CCOCC3)c(ncn2)Nc4ccc(c(c4)Cl)F
InChiKey=XGALLCVXEZPNRQ-UHFFFAOYSA-N",2003,US-5770599-A,Achiral Molecule,"Iressa
Gefitinib
Iressa
ZD-1839",Y,
Gilteritinib,Xospata,4,Astellas Pharma,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'C6F',6jqr,nan,1,552.4,2.7,121.1,10,3,9,"On november 28, 2018, the FDA approved gilteritinib to treat patients who have relapsed or refractory acute myeloid leukemia (AML)","FLT3
AXL
ALK",Tyr,"Smiles=CCc1c(nc(c(n1)C(=O)N)Nc2ccc(c(c2)OC)N3CCC(CC3)N4CCN(CC4)C)NC5CCOCC5
InChiKey=GYQYAJJFPNQOOW-UHFFFAOYSA-N",2018,nan,Achiral Molecule,"ASP-2215
Gilteritinib",Y,
Glesatinib,nan,2,Mirati Therapeutics,"ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS",NaN,NaN,nan,2,619.2,6.2,97.4,8,3,11,nan,"MET
TEK
FLT1
KDR
FLT4
MST1R",Tyr,"Smiles=COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=S)NC(=O)Cc5ccc(cc5)F
InChiKey=YRCHYHRCBXNYNU-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MG90265H9
MG90265gly
MGCD265
MG90265
MG90265X
Glesatinib",,
Golvatinib,nan,2,Eisai,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'GV0',5ia5,2,1,633.3,4.8,119.1,7,3,8,nan,"MET
KDR",Tyr,"Smiles=CN1CCN(CC1)C2CCN(CC2)C(=O)Nc3cc(ccn3)Oc4ccc(c(c4)F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
InChiKey=UQRCJCNVNUFYDX-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"E-7050
Golvatinib
E7050",,
Henatinib,nan,1,Jiangsu Hengrui Medicine,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,468.2,2,97.9,5,3,5,nan,KDR,Tyr,"Smiles=Cc1c([nH]c2c1C(=O)N(CCC2)C[C@@H](CN3CCOCC3)O)/C=C\4/c5cc(ccc5NC4=O)F
InChiKey=MCTXSDCWFQAGFS-UEXNTNOUSA-N",nan,nan,Single Stereoisomer,,,
Ibrutinib,Imbruvica,4,Pharmacyclics,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'1E8',4ifg 4rz7 5p9i 5yu9,1.5,0,440.2,4.2,99.2,7,1,5,"Ibrutinib was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia",BTK,Tyr,"Smiles=C=CC(=O)N1CCC[C@H](C1)n2c3c(c(n2)c4ccc(cc4)Oc5ccccc5)c(ncn3)N
InChiKey=XYFPWWZEPKGCCK-GOSISDBHSA-N",2013,US-7514444-B2,Single Stereoisomer,"Imbruvica
PCI-32765
PCI-32765-00
Ibrutinib
CRA-032765",Y,149-158
Icotinib,nan,4,Zhejiang Beta Pharma,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,391.2,3.2,74.7,7,1,2,"Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor, exhibits encouraging efficacy and tolerability in patients with advanced non-small-cell lung cancer (NSCLC) who failed previous chemotherapy.",EGFR,Tyr,"Smiles=C#Cc1cccc(c1)Nc2c3cc4c(cc3ncn2)OCCOCCOCCO4
InChiKey=QQLKULDARVNMAL-UHFFFAOYSA-N",2011,nan,nan,BPI-2009H,N,
Idelalisib,Zydelig,4,Gilead Sciences,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'40L',4xe0,1,0,415.2,3.8,101.4,7,2,5,"Idelalisib is indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies.",PIK3CD,Atypical,"Smiles=CC[C@@H](c1nc2cccc(c2c(=O)n1c3ccccc3)F)Nc4c5c([nH]cn5)ncn4
InChiKey=IFSDAJWBUCMOAH-HNNXBMFYSA-N",2014,US-6800620-B2,Single Stereoisomer,"Zydelig
GS-1101
GS-11CAL-101
Idelalisib
CAL-101",Y,
Ilorasertib,nan,2,Abbott Laboratories,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,488.1,5.2,118.1,7,4,6,nan,"AURKA
AURKB
AURKC
FLT1
PDGFRA
PDGFRB","Tyr
Other","Smiles=c1cc(cc(c1)F)NC(=O)Nc2ccc(cc2)c3csc4c3c(ncc4c5cnn(c5)CCO)N
InChiKey=WPHKIQPVPYJNAX-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"A-968660
ABT-348
Ilorasertib",,
Imatinib,Gleevec,4,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'STI',1iep 1opj 1t46 1xbb 2hyy 2oiq 2pl0 3fw1 3gvu 3hec 3k5v 3ms9 3mss 3oez 3pyy 4bkj 4csv 4r7i 5mqt 6hd4 6hd6 6npe 6npu 6npv,2,0,493.3,4.6,86.3,7,2,7,"For the treatment of Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML), Ph+ acute lymphoblastic leukaemia, myelodysplastic/myeloproliferative diseases, aggressive systemic mastocytosis, hypereosinophilic syndrome and/or chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans, and malignant gastrointestinal stromal tumors (GIST).","KIT
RET
NTRK1
CSF1R
PDGFRA
DDR1
ABL1
PDGFRB",Tyr,"Smiles=Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C
InChiKey=KTUFNOKKBVMGRW-UHFFFAOYSA-N",2001,US-6894051-B1,Achiral Molecule,"Gleevec
Imatinib
STI-571",Y,226
Infigratinib,nan,2,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'07J',3tt0,1,2,559.2,5.4,95.1,8,2,8,nan,"FGFR1
FGFR2
FGFR3",Tyr,"Smiles=CCN1CCN(CC1)c2ccc(cc2)Nc3cc(ncn3)N(C)C(=O)Nc4c(c(cc(c4Cl)OC)OC)Cl
InChiKey=QADPYRIHXKWUSV-UHFFFAOYSA-N",nan,nan,nan,"BGJ-398
NVP-BGJ398",,
Ipatasertib,nan,3,Hoffmann-La Roche,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'0RF',4ekl,1,0,457.2,3.1,81.6,6,2,6,nan,"AKT1
AKT2
AKT3",AGC,"Smiles=C[C@@H]1C[C@H](c2c1c(ncn2)N3CCN(CC3)C(=O)[C@H](CNC(C)C)c4ccc(cc4)Cl)O
InChiKey=GRZXWCHAXNAUHY-NSISKUIASA-N",nan,nan,Single Stereoisomer,"GDC-0068
Ipatasertib
RG-7440",,
Itacitinib,nan,3,Incyte Corporation,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,553.2,3.6,119.6,8,1,5,nan,JAK1,Tyr,"Smiles=c1cnc-2[nH]cnc(c12)c3cnn(c3)C4(CN(C4)C5CCN(CC5)C(=O)c6ccnc(c6F)C(F)(F)F)CC#N
InChiKey=KTBSXLIQKWEBRB-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"INCB-039110
INCB-39110
Itacitinib
INCB039110",,
Lapatinib,Tykerb,4,GlaxoSmithKline,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'FMM',1xkk 3bbt,1.5,2,580.1,6.1,106.4,8,2,11,"Indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress the human epidermal receptor type 2 (HER2) protein and who have received prior therapy including an anthracycline, a taxane, and trastuzuma.","EGFR
ERBB2",Tyr,"Smiles=CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F
InChiKey=BCFGMOOMADDAQU-UHFFFAOYSA-N",2007,US-6391874-B1,Achiral Molecule,"Tyverb
GW-2016
GW-572016
Lapatinib",Y,
Larotrectinib,Vitrakvi,4,Array BioPharma,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,428.2,2.9,86,6,2,3,"On november 26, 2018, the FDA approved larotrectinib to treat patients whose cancers have a specific genetic feature (biomarker)","NTRK1
NTRK2
NTRK3",Tyr,"Smiles=c1cc(c(cc1F)[C@H]2CCCN2c3ccn4c(n3)c(cn4)NC(=O)N5CC[C@@H](C5)O)F
InChiKey=NYNZQNWKBKUAII-KBXCAEBGSA-N",2018,nan,Single Stereoisomer,"Larotrectinib
LOXO-101",Y,
Lazertinib,nan,1,Genosco,"ChemSpider
PubChem
Guide to Pharmacology
FDA SRS",NaN,NaN,nan,1,554.3,4.1,109.7,10,2,10,"Lazertinib (YH-25448, GNS-1480) is an inhibitor of the aberrant activity of EGFR mutant kinases, that was originally developed by Yuhan Corporation for antineoplastic potential in cancers with (acquired) resistance to existing EGFR tyrosine kinase inhibitors, in particular for EGFR mutation positive, advanced non-small cell lung cancer (NSCLC). In addition to predicted efficacy for the treatment of primary lung and extracranial lesions, lazertinib is expected to be beneficial for NSCLC brain metastases as it is able to cross the blood brain barrier.",nan,,"Smiles=CN(C)Cc1cn(nc1c2ccccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N5CCOCC5)NC(=O)C=C
InChiKey=RRMJMHOQSALEJJ-UHFFFAOYSA-N",nan,nan,nan,,,
Leniolisib,nan,0,Novartis,"ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'9NQ',5o83,nan,0,450.2,2.9,83.5,7,1,5,nan,nan,,"Smiles=CCC(=O)N1CC[C@@H](C1)Nc2c3c(ncn2)CCN(C3)c4cc(c(nc4)OC)C(F)(F)F
InChiKey=MWKYMZXCGYXLPL-ZDUSSCGKSA-N",nan,nan,Single Stereoisomer,"CDZ173-NX
Leniolisib",,
Lenvatinib,Kisplyx;Lenvima,4,Eisai,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'LEV',3wzd 5zv2,1.5,0,426.1,4.1,115.6,5,3,6,"Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer.","FLT1
KDR
FLT4
FGFR1
FGFR2
FGFR3
FGFR4
KIT",Tyr,"Smiles=COc1cc2c(cc1C(=O)N)c(ccn2)Oc3ccc(c(c3)Cl)NC(=O)NC4CC4
InChiKey=WOSKHXYHFSIKNG-UHFFFAOYSA-N",2015,US-7253286-B2,Achiral Molecule,"Lenvima;Kisplyx
ER-203492-00
Lenvatinib",Y,
Lestaurtinib,nan,3,Cephalon,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,439.2,3.5,88.7,6,3,1,nan,FLT3,Tyr,"Smiles=C[C@@]12[C@](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)(CO)O
InChiKey=UIARLYUEJFELEN-LROUJFHJSA-N",nan,nan,Single Stereoisomer,"KT-5555
KT-555
Lestaurtinib
SPM-924
SP-924
A-154475
CEP-701
Cep-701
SP924
A-1544750",,
Linifanib,nan,3,Abbott Laboratories,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,375.1,4.9,95.8,3,4,3,nan,"FLT3
CSF1R
KDR",Tyr,"Smiles=Cc1ccc(c(c1)NC(=O)Nc2ccc(cc2)c3cccc4c3c(n[nH]4)N)F
InChiKey=MPVGZUGXCQEXTM-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"ABT-869
RG-3635
Linifanib
AL-39324",,
Linsitinib,nan,3,Osi Pharmaceuticals,"ChemSpider
ChEMBL
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,421.2,4.8,89.3,6,2,3,nan,IGF1R,Tyr,"Smiles=C[C@]1(C[C@@H](C1)c2n3c(c(ncc3)N)c(n2)c4cc5nc(ccc5cc4)c6ccccc6)O
InChiKey=PKCDDUHJAFVJJB-VLZXCDOPSA-N",nan,nan,Single Stereoisomer,"Linsitinib
ASP-7487
OSI-906
OSI-906AA",,
Lorlatinib,Lorbrena,4,Pfizer,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'5P8',4cli 4clj 4uxl 5a9u 5aa8 5aa9,1,0,406.2,2.8,110.1,7,1,0,"On november 2, 2018, the FDA approved lorlatinib to treat patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer","ALK
ROS1",Tyr,"Smiles=C[C@@H]1c2cc(ccc2C(=O)N(Cc3c(c(n(n3)C)C#N)-c4cc(c(nc4)N)O1)C)F
InChiKey=IIXWYSCJSQVBQM-LLVKDONJSA-N",2018,nan,Single Stereoisomer,"Lorlatinib
PF-06463922",Y,
Losmapimod,nan,3,GlaxoSmithKline,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,383.2,3.9,71.1,3,2,5,nan,"MAPK14
MAPK11
MAPK13
MAPK12",CMGC,"Smiles=Cc1c(cc(cc1F)C(=O)NC2CC2)c3ccc(cn3)C(=O)NCC(C)(C)C
InChiKey=KKYABQBFGDZVNQ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"GSKAHAB
GW856553
GW856553X
Losmapimod",,
Lucitanib,nan,2,Clovis Oncology,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'3ZC',4rwl,1,0,443.2,4.4,95.7,6,2,7,nan,"FLT1
KDR
FLT4
FGFR1
FGFR2",Tyr,"Smiles=CNC(=O)c1cccc2c1ccc(c2)Oc3ccnc4c3cc(c(c4)OCC5(CC5)N)OC
InChiKey=CUDVHEFYRIWYQD-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"E-3810
CO-3810
Lucitanib
S-80881
AL-3810",,
Masitinib,Kinavet;Masivet,3,AB Science,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'G65',5mql,nan,1,498.2,5.3,73.4,7,2,7,nan,"KIT
PDGFRA
PDGFRB
FGFR1
FGFR2
FGFR3",Tyr,"Smiles=Cc1ccc(cc1Nc2nc(cs2)c3cccnc3)NC(=O)c4ccc(cc4)CN5CCN(CC5)C
InChiKey=WJEOLQLKVOPQFV-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Masivet;Kinavet
Masitinib
AB-1010",,
Mavelertinib,nan,0,Pfizer,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,415.2,0.7,115,10,2,6,nan,nan,,"Smiles=Cn1cc(c(n1)OC)Nc2c3c(nc(n2)N4C[C@H]([C@@H](C4)F)NC(=O)C=C)n(cn3)C
InChiKey=JYIUNVOCEFIUIU-GHMZBOCLSA-N",nan,nan,Single Stereoisomer,"PF-06747775
Mavelertinib",,
Merestinib,nan,2,Eli Lilly,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'L1X',4eev,2,2,552.2,5.7,106.8,7,2,6,nan,MET,Tyr,"Smiles=Cc1ccc(c(=O)n1c2ccc(cc2)F)C(=O)Nc3ccc(c(c3)F)Oc4cc5cnn(c5cc4c6c[nH]nc6)C
InChiKey=QHADVLVFMKEIIP-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Merestinib
LY-2801653",,
Midostaurin,Rydapt,4,Novartis Pharmaceuticals Corp,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'2K2',4nct,nan,2,570.2,5.9,77.7,6,1,3,"On april 28 , 2017, the FDA approved midostaurin to treat acute myeloid leukemia",nan,,"Smiles=C[C@@]12[C@@H]([C@@H](C[C@@H](O1)n3c4ccccc4c5c3c6n2c7ccccc7c6c8c5C(=O)NC8)N(C)C(=O)c9ccccc9)OC
InChiKey=BMGQWWVMWDBQGC-IIFHNQTCSA-N",2017,US-7973031-B2,Single Stereoisomer,"Rydapt
Midostaurin
NVP-PKC412
PKC-412
CGP-41251",Y,235-260
Milciclib,nan,2,Nerviano Medical Sciences,"ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'P48',2wih 5vc6 5vd1,1,0,460.3,2.6,91.2,8,2,4,nan,"CDK1
NTRK1","Tyr
CMGC","Smiles=CC1(Cc2cnc(nc2-c3c1c(nn3C)C(=O)NC)Nc4ccc(cc4)N5CCN(CC5)C)C
InChiKey=RXZMYLDMFYNEIM-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"PHA-848125
Milciclib",,
Momelotinib,nan,3,Ym Biosciences Australia,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'C87',6fdz,nan,0,414.2,3,103.2,7,2,6,nan,"JAK1
JAK2
JAK3",Tyr,"Smiles=c1cc(ccc1c2ccnc(n2)Nc3ccc(cc3)N4CCOCC4)C(=O)NCC#N
InChiKey=ZVHNDZWQTBEVRY-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"CYT-11387
GS-0387
Momelotinib
CYT-387",,
Motesanib,nan,3,Amgen,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'706',3efl,2,0,373.2,4,78.9,5,3,5,nan,"FLT1
KDR
FLT4
PDGFRA
PDGFRB
KIT
RET",Tyr,"Smiles=CC1(CNc2c1ccc(c2)NC(=O)c3cccnc3NCc4ccncc4)C
InChiKey=RAHBGWKEPAQNFF-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"AMG-706
Motesanib",,
Mubritinib,nan,1,Takeda,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,1,468.2,6.1,66,6,0,10,nan,"EGFR
ERBB2",Tyr,"Smiles=c1cc(ccc1CCCCn2ccnn2)OCc3coc(n3)/C=C/c4ccc(cc4)C(F)(F)F
InChiKey=ZTFBIUXIQYRUNT-MDWZMJQESA-N",nan,nan,Achiral Molecule,"TAK-165
Mubritinib",,
Naquotinib,nan,3,Astellas Pharma,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'8RC',5y9t,nan,1,562.3,2.3,120.2,9,2,9,nan,EGFR,Tyr,"Smiles=CCc1c(nc(c(n1)C(=O)N)Nc2ccc(cc2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C
InChiKey=QKDCLUARMDUUKN-XMMPIXPASA-N",nan,nan,Single Stereoisomer,"Naquotinib
ASP8273",,
Nazartinib,nan,3,Novartis,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,494.2,4.3,83.4,6,1,6,nan,nan,,"Smiles=Cc1cc(ccn1)C(=O)Nc2nc3cccc(c3n2[C@@H]4CCCCN(C4)C(=O)/C=C/CN(C)C)Cl
InChiKey=IOMMMLWIABWRKL-WUTDNEBXSA-N",nan,nan,nan,NAZARTINIB,,
Neflamapimod,nan,2,EIP Pharma,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'52P',3fc1 3hp5 3zsi,nan,1,435,5.5,47.3,5,0,3,nan,MAPK14,CMGC,"Smiles=c1cc(c(c(c1)Cl)c2c3ccc(nn3cnc2=O)Sc4ccc(cc4F)F)Cl
InChiKey=VEPKQEUBKLEPRA-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Neflamapimod
VD-31
VRT-031745
VX-745
745",,
Nemiralisib,nan,0,GlaxosmithKline,"ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'VVX',5ae8,nan,0,440.2,4.9,77,5,2,5,nan,nan,,"Smiles=CC(C)N1CCN(CC1)Cc2cnc(o2)c3cc(cc4c3cn[nH]4)c5cccc6c5cc[nH]6
InChiKey=MCIDWGZGWVSZMK-UHFFFAOYSA-N",nan,nan,Single Stereoisomer,"GSK2269557A
GSK-2269557
Nemiralisib",,
Neratinib,Nerlynx,4,Puma Biotechnology,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,2,556.2,5.9,112.4,8,2,11,"For use as an extended adjuvant treatment in adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy","ERBB2
EGFR",Tyr,"Smiles=CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)OCc4ccccn4
InChiKey=JWNPDZNEKVCWMY-VQHVLOKHSA-N",2017,US-6288082-B1,Achiral Molecule,"WAY-179272
CDP-820
Neratinib
HKI-272",Y,
Netarsudil,Rhopressa,4,Aerie Pharmaceutical,"ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,453.2,4.9,94.3,5,2,7,"On december 18, 2017, the FDA approved netarsudil to treat glaucoma or ocular hypertension",nan,,"Smiles=Cc1ccc(c(c1)C)C(=O)OCc2ccc(cc2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3
InChiKey=OURRXQUGYQRVML-AREMUKBSSA-N",2017,nan,Racemic Mixture,AR-13324,Y,
Nilotinib,Tasigna,4,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'NIL',3cs9 3gp0 5mo4,2,2,529.2,6.4,97.6,7,2,6,"For the potential treatment of various leukemias, including chronic myeloid leukemia (CML).","ABL1
KIT",Tyr,"Smiles=Cc1ccc(cc1Nc2nccc(n2)c3cccnc3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F
InChiKey=HHZIURLSWUIHRB-UHFFFAOYSA-N",2007,US-7169791-B2,Achiral Molecule,"Tasigna
Nilotinib
AMN-107",Y,
Ningetinib,nan,1.5,HEC Pharm,"ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,2,556.2,5.4,107.6,8,2,8,"Ningetinib, also known as CT-053 or DE-120, is a VEGF and PDGF inhibitor potentially for the treatment of wet age-related macular degeneration.",nan,,"Smiles=Cc1c(c(=O)n(n1C)c2ccccc2)C(=O)Nc3ccc(c(c3)F)Oc4ccnc5c4ccc(c5)OCC(C)(C)O
InChiKey=VQYYQSZNRVQLIS-UHFFFAOYSA-N",nan,nan,nan,NINGETINIB,,
Nintedanib,Ofev;Vargatef,4,Boehringer Ingelheim,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'XIN',3c7q 5maf 5te0 6nec,1,1,539.3,3.6,94.2,7,2,7,Nintedanib is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).,"FLT1
KDR
FLT4
FGFR1
FGFR2
FGFR3
FLT3
LCK
LYN
SRC",Tyr,"Smiles=CN1CCN(CC1)CC(=O)N(C)c2ccc(cc2)N/C(=C\3/c4ccc(cc4NC3=O)C(=O)OC)/c5ccccc5
InChiKey=XZXHXSATPCNXJR-ZIADKAODSA-N",2014,US-6762180-B1,Achiral Molecule,"Ofev;Vargatef
Nintedanib
BIBF-1120",Y,
Oclacitinib,nan,0,Pfizer,"ChemSpider
ChEMBL
Guide to Pharmacology
FDA SRS
BindingDB",NaN,NaN,nan,0,337.2,1.5,91,5,2,5,nan,"JAK1
JAK2
JAK3",Tyr,"Smiles=CNS(=O)(=O)C[C@H]1CC[C@@H](CC1)N(c2ncnc3c2cc[nH]3)C
InChiKey=HJWLJNBZVZDLAQ-HAQNSBGRSA-N",nan,nan,Single Stereoisomer,"Oclacitinib
JAKI
PF-03394197",,
Olmutinib,nan,2,Hanmi Pharmaceutical,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,486.2,5.1,82.6,8,2,7,For use in treatment of metastatic T790M mutation positive non-small cell lung cancer,EGFR,Tyr,"Smiles=CN1CCN(CC1)c2ccc(cc2)Nc3nc4ccsc4c(n3)Oc5cccc(c5)NC(=O)C=C
InChiKey=FDMQDKQUTRLUBU-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"BI 1482694
Olmutinib
HM61713
HM-61713",,
Omipalisib,nan,1,GlaxosmithKline,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'ZIG',3l08,1,1,505.1,4.8,107,7,1,6,nan,"PIK3CA
MTOR",Atypical,"Smiles=COc1c(cc(cn1)c2ccc3c(c2)c(ccn3)c4ccnnc4)NS(=O)(=O)c5ccc(cc5F)F
InChiKey=CGBJSGAELGCMKE-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Omipalisib
GSK2126458",,
Orantinib,nan,3,Pfizer,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'SU6',4jlc 5yvc,1,0,310.1,3.1,82.2,2,3,4,nan,"KDR
PDGFRB
FGFR1",Tyr,"Smiles=Cc1c(c([nH]c1/C=C\2/c3ccccc3NC2=O)C)CCC(=O)O
InChiKey=NHFDRBXTEDBWCZ-ZROIWOOFSA-N",nan,nan,Achiral Molecule,"TSU-68
SU-6668
Orantinib",,
Osimertinib,Tagrisso,4,Astrazeneca,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'YY3',4zau,1,0,499.3,4.5,87.6,8,2,10,"Osimertinib is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA- approved test, who have progressed on or after EGFR-TKI therapy.",EGFR,Tyr,"Smiles=Cn1cc(c2c1cccc2)c3ccnc(n3)Nc4cc(c(cc4OC)N(C)CCN(C)C)NC(=O)C=C
InChiKey=DUYJMQONPNNFPI-UHFFFAOYSA-N",2015,US-8946235-B2,Achiral Molecule,"Tagrisso
Osimertinib
AZD-9291",Y,
Pacritinib,nan,3,Cell Therapeutics,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'6T3',5lbz,nan,0,472.2,5,68.7,7,1,4,nan,JAK2,Tyr,"Smiles=c1cc2cc(c1)-c3ccnc(n3)Nc4ccc(c(c4)COC/C=C/COC2)OCCN5CCCC5
InChiKey=HWXVIOGONBBTBY-ONEGZZNKSA-N",nan,nan,Achiral Molecule,"ONX-0803
SB-1518
SB1518
Pacritinib",,
Palbociclib,Ibrance,4,Pfizer,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'LQQ',2euf 5l2i,1,0,447.2,3,105,9,2,5,"Palbociclib is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.","CDK4
CDK6",CMGC,"Smiles=Cc1c2cnc(nc2n(c(=O)c1C(=O)C)C3CCCC3)Nc4ccc(cn4)N5CCNCC5
InChiKey=AHJRHEGDXFFMBM-UHFFFAOYSA-N",2015,US-6936612-B2,Achiral Molecule,"Ibrance
Palbociclib
PD-0332991",Y,263-266
Pamapimod,nan,2,Hoffmann-La Roche,"ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'FLW',3flw,1,0,406.1,1.9,109.5,8,3,8,nan,"MAPK14
MAPK11",CMGC,"Smiles=Cn1c2c(cc(c1=O)Oc3ccc(cc3F)F)cnc(n2)NC(CCO)CCO
InChiKey=JYYLVUFNAHSSFE-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"R-1503
JTT-705
Pamapimod
Ro-4402257",,
Panulisib,nan,1,Piramal Enterprises,"ChemSpider
PubChem
Guide to Pharmacology
ZINC",NaN,NaN,nan,1,527.2,4.8,134.5,9,1,3,nan,"PIK3CA
MTOR",Atypical,"Smiles=CC(C)(C#N)c1ccc(cn1)n2c3c4cc(ccc4ncc3n(c2=NC#N)C)c5cc(c(nc5)N)C(F)(F)F
InChiKey=VJLRLTSXTLICIR-UHFFFAOYSA-N",nan,nan,Single Stereoisomer,,,
Parsaclisib,nan,2,Incyte Corporation,"ChemSpider
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
BindingDB",NaN,NaN,nan,0,432.1,3.1,107.9,7,2,5,"Parsaclisib (INCB050465) is a PI3Kδ inhibitor that was developed by Incyte Corporation as an antineoplastic and immunomodulatory agent, as claimed in their patent WO2014134426A1 [1]. The chemical structure is one of those claimed in patent WO2013033569A1, but it is not clear which example it is from a mixture of diastereoisomers 345-348 (although 347 and 348 had the highest inhibitory potency vs. PI3Kδ and 347 was tested in vivo [2].",nan,,"Smiles=CCOc1c(cc(c(c1[C@H]2CC(=O)NC2)F)Cl)[C@H](C)n3c4c(c(n3)C)c(ncn4)N
InChiKey=ZQPDJCIXJHUERQ-QWRGUYRKSA-N",nan,nan,nan,INCB050465,,
Pazopanib,Votrient,4,GlaxoSmithKline,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,1,0,437.2,3.1,119,8,2,5,Treatment of advanced renal cell cancer and advanced soft tissue sarcoma (in patients previously treated with chemotherapy),"FLT1
KDR
FLT4
PDGFRA
PDGFRB
KIT
FGFR3
ITK
FGFR1",Tyr,"Smiles=Cc1ccc(cc1S(=O)(=O)N)Nc2nccc(n2)N(C)c3ccc4c(n(nc4c3)C)C
InChiKey=CUIHSIWYWATEQL-UHFFFAOYSA-N",2009,US-7105530-B2,Achiral Molecule,"Votrient
Pazopanib
GW786034",Y,
Peficitinib,nan,3,Astellas Pharma,"ChemSpider
RCSB
PDBe
ZINC",'9T6',6aah 6aaj 6aak 6aam,nan,0,326.2,2,104,4,4,3,nan,"JAK1
JAK2
JAK3
TYK2",Tyr,"Smiles=c1c[nH]c2c1c(c(cn2)C(=O)N)N[C@@H]3[C@@H]4C[C@@H]5C[C@H]3C[C@@](C5)(C4)O
InChiKey=DREIJXJRTLTGJC-ZKVNVPQCSA-N",nan,nan,Racemic Mixture,"ASP015K
ASP015K hydrobromide",,
Pelitinib,nan,2,Wyeth,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'93J',5vcw,1,1,467.2,5.1,90.3,6,2,8,nan,"EGFR
ERBB2",Tyr,"Smiles=CCOc1cc2c(cc1NC(=O)/C=C/CN(C)C)c(c(cn2)C#N)Nc3ccc(c(c3)Cl)F
InChiKey=WVUNYSQLFKLYNI-AATRIKPKSA-N",nan,nan,Achiral Molecule,"WAY-EKB-569
EKB-569
Pelitinib",,
Pexidartinib,Turalio,4,Daiichi Sankyo,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'P31',4r7h,2,1,417.1,5.2,66.5,4,2,5,"On august 2019, FDA approved pexidartinib to treat adult patients with symptomatic tenosynovial giant cell tumor","FLT3
KIT
CSF1R",Tyr,"Smiles=c1cc(ncc1Cc2c[nH]c3c2cc(cn3)Cl)NCc4ccc(nc4)C(F)(F)F
InChiKey=JGWRKYUXBBNENE-UHFFFAOYSA-N",2019,nan,Achiral Molecule,"CML-261
Pexidartinib
PLX3397",Y,
Pexmetinib,nan,1,Array BioPharma,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,2,556.3,6.1,106.2,7,3,8,nan,"MAPK14
TEK","Tyr
CMGC","Smiles=Cc1ccc(cc1)n2c(cc(n2)C(C)(C)C)NC(=O)NCc3cc(ccc3Oc4ccc5c(c4)cnn5CCO)F
InChiKey=LNMRSSIMGCDUTP-UHFFFAOYSA-N",nan,nan,Single Stereoisomer,,,
Pictilisib,nan,2,Hoffmann-La Roche,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'GD9',2wxp 2y3a 3dbs,1,1,513.2,2.1,107.6,9,1,5,nan,"PIK3CA
PIK3CB
PIK3CD
PIK3CG",Atypical,"Smiles=CS(=O)(=O)N1CCN(CC1)Cc2cc3c(s2)c(nc(n3)c4cccc5c4cn[nH]5)N6CCOCC6
InChiKey=LHNIIDJUOCFXAP-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"RG-7321
GDC-0941
Pictilisib",,
Pilaralisib,nan,2,Sanofi,"ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,540.1,4.5,148.3,8,4,8,nan,"PIK3CA
PIK3CB
PIK3CD
PIK3CG",Atypical,"Smiles=CC(C)(C(=O)Nc1cccc(c1)S(=O)(=O)Nc2c(nc3ccccc3n2)Nc4cc(ccc4Cl)OC)N
InChiKey=QINPEPAQOBZPOF-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Pilaralisib
SAR-245408
XL-147",,
Pimasertib,nan,2,Merck,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,431,1.7,94.5,5,4,6,nan,"MAP2K1
MAP2K2",STE,"Smiles=c1cc(c(cc1I)F)Nc2cnccc2C(=O)NC[C@@H](CO)O
InChiKey=VIUAUNHCRHHYNE-JTQLQIEISA-N",nan,nan,Single Stereoisomer,"MSC1936369A; AS703026; EMD 1036239
AS-703026
MSC-1936369B
EMD 1036239
Pimasertib",,
Ponatinib,Iclusig,4,Ariad Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'0LI',3ik3 3oxz 3zos 4c8b 4qrc 4tyj 4u0i 4uxq 4v01 4v04 6eg9,2,1,532.2,4.5,65.8,6,1,4,"Ponatinib is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.","ABL1
BCR
KIT
RET
TEK
FLT3
FGFR1
FGFR2
FGFR3
FGFR4
LCK
SRC
LYN
KDR
PDGFRA","Atypical
Tyr","Smiles=Cc1ccc(cc1C#Cc2cnc3n2nccc3)C(=O)Nc4ccc(c(c4)C(F)(F)F)CN5CCN(CC5)C
InChiKey=PHXJVRSECIGDHY-UHFFFAOYSA-N",2012,US-8114874-B2,Achiral Molecule,"Iclusig
AP-24534
Ponatinib",Y,
Poziotinib,nan,2,Hanmi Pharmaceutical,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,1,490.1,5.4,76.6,6,1,6,nan,EGFR,Tyr,"Smiles=COc1cc2c(cc1OC3CCN(CC3)C(=O)C=C)c(ncn2)Nc4ccc(c(c4F)Cl)Cl
InChiKey=LPFWVDIFUFFKJU-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"NOV-120101
Poziotinib
HM-781-36B",,
Pralsetinib,nan,1.5,Blueprint Medicines,"ChemSpider
FDA SRS",NaN,NaN,nan,1,533.3,4.2,135.5,9,3,8,"Pralsetinib, also known as BLU-667, is a highly potent, selective, next generation RET inhibitor. BLU-667 is a potent and selective inhibitor of RET mutations, fusions, and predicted resistant mutants. RET fusions are key drivers of multiple cancers, including lung and thyroid cancer, and our research suggests that RET also plays a key role in some colon and breast cancers. By simultaneously targeting the primary driver and predicted resistant mutants that render cancer cells insensitive to treatment with currently approved drugs",nan,,"Smiles=Cc1[nH]nc(c1)Nc2nc(nc(c2)C)[C@H]3CC[C@@](CC3)(OC)C(=O)N[C@H](c4cnc(cc4)n5ncc(c5)F)C
InChiKey=GBLBJPZSROAGMF-BATDWUPUSA-N",nan,nan,nan,BLU-667,,
Prexasertib,nan,2,Eli Lilly,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,365.2,2.2,134.8,8,3,8,nan,"CHEK1
CHEK2",CAMK,"Smiles=COc1cccc(c1c2cc(n[nH]2)Nc3cnc(cn3)C#N)OCCCN
InChiKey=DOTGPNHGTYJDEP-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"LY-2606368
Prexasertib",,
Pyrotinib,nan,3,Hengrui Therapeutics,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,2,582.2,6.5,112.4,8,2,10,nan,"EGFR
ERBB2",Tyr,"Smiles=CCOc1cc2c(cc1NC(=O)/C=C/[C@H]3CCCN3C)c(c(cn2)C#N)Nc4ccc(c(c4)Cl)OCc5ccccn5
InChiKey=SADXACCFNXBCFY-IYNHSRRRSA-N",nan,nan,Single Stereoisomer,SHR1258,,
Quizartinib,nan,3,Ambit Biosciences,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'P30',4rt7 4xuf,2,2,560.2,5.9,106.2,9,2,7,nan,"FLT3
CSF1R
KIT",Tyr,"Smiles=CC(C)(C)c1cc(no1)NC(=O)Nc2ccc(cc2)c3cn4c5ccc(cc5sc4n3)OCCN6CCOCC6
InChiKey=CVWXJKQAOSCOAB-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"ASP-2689
AC220
Quizartinib
AC010220
AC-220",,
Rabusertib,nan,2,Eli Lilly,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,435.1,2.9,97.4,6,3,5,nan,CHEK1,CAMK,"Smiles=Cc1cc(c(cc1Br)NC(=O)Nc2cnc(cn2)C)OC[C@@H]3CNCCO3
InChiKey=SYYBDNPGDKKJDU-ZDUSSCGKSA-N",nan,nan,Single Stereoisomer,"Rabusertib
LY-2603618
IC-83",,
Radotinib,nan,3,Il-Yang Pharmaceutical,"ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,2,530.2,5.8,110.5,8,2,6,"Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.","ABL1
PDGFRB",Tyr,"Smiles=Cc1ccc(cc1Nc2nccc(n2)c3cnccn3)C(=O)Nc4cc(cc(c4)n5cc(nc5)C)C(F)(F)F
InChiKey=DUPWHXBITIZIKZ-UHFFFAOYSA-N",nan,nan,nan,"SUPEC
IY5511HCL",,
Ralimetinib,nan,2,Eli Lilly,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,1,420.2,5.6,85.4,5,2,3,nan,"MAPK14
MAPK11",CMGC,"Smiles=CC(C)(C)Cn1c2c(ccc(n2)c3c(nc([nH]3)C(C)(C)C)c4ccc(cc4)F)nc1N
InChiKey=XPPBBJCBDOEXDN-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"LY-2228820
LY-22288220
Ralimetinib",,
Ravoxertinib,nan,1,Genentech,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'6QB',5k4i 5k4j 6oph,nan,0,440.1,3.2,97.9,8,2,6,nan,nan,,"Smiles=Cn1c(ccn1)Nc2nccc(n2)c3ccn(c(=O)c3)[C@H](CO)c4ccc(c(c4)F)Cl
InChiKey=RZUOCXOYPYGSKL-GOSISDBHSA-N",nan,nan,Single Stereoisomer,"Ravoxertinib
RG-7842
GDC-0994",,
Rebastinib,nan,2,Deciphera Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'919',3qri 3qrj 5g6v 6cnh 6mwe,2,2,553.2,6,123.1,7,3,6,nan,"FLT3
TEK
KDR
LYN
BCR
ABL1
NTRK1","Atypical
Tyr","Smiles=CC(C)(C)c1cc(n(n1)c2ccc3c(c2)cccn3)NC(=O)Nc4ccc(cc4F)Oc5ccnc(c5)C(=O)NC
InChiKey=WVXNSAVVKYZVOE-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"DP-1919
DP-1919
DCC-2036
Rebastinib",,
Recilisib,Ex-RAD,1,Onconova Therapeutics,"ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS",NaN,NaN,nan,0,336,3.6,71.4,3,1,5,nan,nan,,"Smiles=c1cc(ccc1CS(=O)(=O)/C=C/c2ccc(cc2)C(=O)O)Cl
InChiKey=KBEKQQJUNVQLDZ-MDZDMXLPSA-N",nan,nan,Achiral Molecule,"Ex-RAD
ON-01210
ON-01210.Na
Recilisib",,
Refametinib,nan,2,Bayer,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS",'VRA',3e8n,nan,1,572,3.5,107.9,6,4,9,nan,MAP2K1,STE,"Smiles=COc1cc(c(c(c1NS(=O)(=O)C2(CC2)C[C@@H](CO)O)Nc3ccc(cc3F)I)F)F
InChiKey=RDSACQWTXKSHJT-NSHDSACASA-N",nan,nan,Single Stereoisomer,"BAY-86-9766
Refametinib
RDEA-119",,
Regorafenib,Stivarga,4,Bayer,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,2,1,482.1,5.7,92.3,4,3,5,"Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.","FLT1
KDR
FLT4
KIT
PDGFRA
PDGFRB
FGFR1
FGFR2
TEK
DDR2
NTRK1
EPHA2
RAF1
BRAF
MAPK11
FRK
ABL1
RET","TKL
Tyr
CMGC","Smiles=CNC(=O)c1cc(ccn1)Oc2ccc(c(c2)F)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl
InChiKey=FNHKPVJBJVTLMP-UHFFFAOYSA-N",2012,US-7351834-B1,Achiral Molecule,"Stivarga
Regorafenib
BAY-734506 monohydrate
BAY-73-4506",Y,
Ribociclib,Kisqali,4,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'6ZZ',5l2t,1,0,434.3,2.8,91.2,8,2,5,"Kisqali (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably.","CDK4
CDK6",CMGC,"Smiles=CN(C)C(=O)c1cc2cnc(nc2n1C3CCCC3)Nc4ccc(cn4)N5CCNCC5
InChiKey=RHXHGRAEPCAFML-UHFFFAOYSA-N",2017,US-8324225-B2,Achiral Molecule,"Ribociclib
LEE-011
NVP-LEE011",Y,
Rigosertib,nan,3,Onconova Therapeutics,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'6FS',5j18 5j2r 5ov7,3,0,451.1,2.8,120.4,8,2,11,nan,"PIK3CA
PLK1","Atypical
Other","Smiles=COc1ccc(cc1NCC(=O)O)CS(=O)(=O)/C=C/c2c(cc(cc2OC)OC)OC
InChiKey=OWBFCJROIKNMGD-BQYQJAHWSA-N",nan,nan,Achiral Molecule,"Rigosertib
ON-01910",,
Ripasudil,nan,2,Kowa Pharmaceutical,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,323.1,1.7,62.3,4,1,2,nan,nan,,"Smiles=C[C@H]1CNCCCN1S(=O)(=O)c2cccc3c2c(cnc3)F
InChiKey=QSKQVZWVLOIIEV-NSHDSACASA-N",nan,nan,nan,RIPASUDIL,,
Ripretinib,nan,3,Deciphera Pharmaceuticals,"ChemSpider
PubChem
DrugBank
Guide to Pharmacology
FDA SRS",NaN,NaN,nan,2,509.1,5.7,88,5,3,5,"Ripretinib (DCC-2618) is an orally bioavailable, potent pan-KIT and PDGFRα kinase inhibitor being developed by Dicephera Pharmaceuticals. It is in clinical development for the treatment of malignancies that are driven by KIT and/or PDGFRα, for example gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Ripretinib has activity across a broad range of resistance mutations in its target kinases, that emerge in response to imatinib treatment. Ripretinib binds to the 'switch pocket' of KIT, a domain that regulates the enzyme's catalytic conformation. Compounds that act in this way are often referred to as switch control inhibitors.",nan,,"Smiles=CCn1c2cc(ncc2cc(c1=O)c3cc(c(cc3Br)F)NC(=O)Nc4ccccc4)NC
InChiKey=CEFJVGZHQAGLHS-UHFFFAOYSA-N",nan,nan,nan,"DCC-2618
RIPRETINIB",,
Riviciclib,nan,2,Piramal Enterprises,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,401.1,3.3,94.1,6,3,3,nan,"CDK1
CDK4
CDK9",CMGC,"Smiles=CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccccc4Cl)O)O
InChiKey=QLUYMIVVAYRECT-OCCSQVGLSA-N",nan,nan,Racemic Mixture,,,
Rivoceranib,nan,1,Advenchen Laboratories,"ChemSpider
ChEMBL
PubChem
FDA SRS
BindingDB",NaN,NaN,nan,0,493.2,4.2,145.1,7,3,6,Rivoceranib Mesylate is a novel selective inhibitor of vascular endothelial growth factor receptor 2 (vegfr2),nan,,"Smiles=CS(=O)(=O)O.c1cc(c(nc1)NCc2ccncc2)C(=O)Nc3ccc(cc3)C4(CCCC4)C#N
InChiKey=FYJROXRIVQPKRY-UHFFFAOYSA-N",nan,nan,nan,YN-968D1,,
Rociletinib,nan,3,Clovis Oncology,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'8JC',5xdk 5xdl,1,1,555.2,4.8,111.7,8,3,8,nan,EGFR,Tyr,"Smiles=CC(=O)N1CCN(CC1)c2ccc(c(c2)OC)Nc3ncc(c(n3)Nc4cccc(c4)NC(=O)C=C)C(F)(F)F
InChiKey=HUFOZJXAKZVRNJ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"CNX-419
AVL-301
CO-1686
Rociletinib",,
Rogaratinib,nan,2,Bayer,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
FDA SRS
BindingDB",NaN,NaN,nan,0,466.2,2.6,107,9,2,6,Rogaratinib (BAY-1163877) is a FGFR-selective kinase inhibitor that is being investigated for antineoplastic activity.,nan,,"Smiles=Cc1cc2cc(sc2c(c1)OC)c3c(c(n4c3c(ncn4)N)CN5CCNC(=O)C5)COC
InChiKey=HNLRRJSKGXOYNO-UHFFFAOYSA-N",nan,nan,nan,"ROGARATINIB
BAY 1163877",,
Roniciclib,nan,2,Bayer,"ChemSpider
PubChem
DrugBank
ZINC
FDA SRS",NaN,NaN,nan,0,430.1,4,108.2,7,3,7,nan,"CDK1
CDK2
CDK4
CDK9",CMGC,"Smiles=C[C@H]([C@@H](C)Oc1c(cnc(n1)Nc2ccc(cc2)[S@](=N)(=O)C3CC3)C(F)(F)F)O
InChiKey=UELYDGOOJPRWGF-SRQXXRKNSA-N",nan,nan,Single Stereoisomer,,,
Ruboxistaurin,Arxxant,3,Eli Lilly,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'LY4',1uu3 2j2i,nan,0,468.2,3.5,68.5,6,1,2,nan,nan,,"Smiles=CN(C)C[C@@H]1CCn2cc(c3c2cccc3)C4=C(c5cn(c6c5cccc6)CCO1)C(=O)NC4=O
InChiKey=ZCBUQCWBWNUWSU-SFHVURJKSA-N",nan,nan,Single Stereoisomer,"Arxxant
LY-333531
Ruboxistaurin",,
Ruxolitinib,Jakafi,4,Incyte Corporation,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'RXT',4u5j,1,0,306.2,3.5,83.2,5,1,4,"Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).","JAK1
JAK2",Tyr,"Smiles=c1c[nH]c2c1c(ncn2)c3cnn(c3)[C@H](CC#N)C4CCCC4
InChiKey=HFNKQEVNSGCOJV-OAHLLOKOSA-N",2011,US-7598257-B2,Single Stereoisomer,"Jakavi
INCB-018424
Ruxolitinib",Y,
Samotolisib,nan,2,Eli Lilly,"ChemSpider
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,406.2,3.2,82.2,7,1,5,"LY3023414 is a dual inhibitor of phosphoinositide 3-kinase α (PI3Kα) and the serine/threonine kinase mTOR (mechanistic target of rapamycin), with potential antineoplastic activity.",nan,,"Smiles=C[C@@H](Cn1c2c3cc(ccc3ncc2n(c1=O)C)c4cc(cnc4)C(C)(C)O)OC
InChiKey=ACCFLVVUVBJNGT-AWEZNQCLSA-N",nan,nan,nan,"LY-3023414
LY 3023414
WHO 10889
LY3023414",,
Sapanisertib,nan,2,Takeda,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'FE5',6gvf,nan,0,309.1,2.4,121.7,8,2,2,nan,MTOR,Atypical,"Smiles=CC(C)n1c2c(c(n1)c3ccc4c(c3)nc(o4)N)c(ncn2)N
InChiKey=GYLDXIAOMVERTK-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MLN-0128
Sapanisertib
TAK-228",,
Sapitinib,nan,2,Astrazeneca,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,473.2,3.8,88.6,7,2,7,nan,"EGFR
ERBB2
ERBB4
ERBB3",Tyr,"Smiles=CNC(=O)CN1CCC(CC1)Oc2cc3c(cc2OC)ncnc3Nc4cccc(c4F)Cl
InChiKey=DFJSJLGUIXFDJP-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Sapitinib
AZD-8931",,
Saracatinib,nan,3,Astrazeneca,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'H8H',2h8h 4qmx 5vcx 5vd3,1,1,541.2,3.9,90.4,10,1,8,nan,"SRC
ABL1",Tyr,"Smiles=CN1CCN(CC1)CCOc2cc3c(c(c2)OC4CCOCC4)c(ncn3)Nc5c(ccc6c5OCO6)Cl
InChiKey=OUKYUETWWIPKQR-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"AZD-0530
Saracatinib
AZ-10353926",,
Savolitinib,nan,3,Astrazeneca,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'V0L',5lbw 6sde,nan,0,345.1,1.9,91.6,9,0,3,nan,MET,Tyr,"Smiles=C[C@@H](c1ccc2nccn2c1)n3c4c(ncc(n4)c5cnn(c5)C)nn3
InChiKey=XYDNMOZJKOGZLS-NSHDSACASA-N",nan,nan,Single Stereoisomer,"AZD-6094
Savolitinib
HMPL-504
AZD6094",,
Selatinib,nan,1,Qilu Pharmaceutical,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
BindingDB",NaN,NaN,nan,2,564.1,6.5,89.3,7,2,11,nan,"EGFR
ERBB2",Tyr,"Smiles=CS(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F
InChiKey=OAMVGUFHZPRXOM-UHFFFAOYSA-N",nan,nan,nan,,,
Seliciclib,nan,2,Cyclacel pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'RRC',1unl 1ygk 2a4l 3ddq,1,0,354.2,3.2,87.9,7,3,8,nan,"CDK2
CDK7
CDK9",CMGC,"Smiles=CC[C@H](CO)Nc1nc(NCc2ccccc2)c3ncn(C(C)C)c3n1
InChiKey=BTIHMVBBUGXLCJ-OAHLLOKOSA-N",nan,nan,Single Stereoisomer,"Seliciclib
CYC-202
AL-39256",,
Selonsertib,nan,2,Gilead Sciences,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'NJV',6oyt,nan,0,445.2,4.7,90.5,7,1,6,nan,MAP3K5,STE,"Smiles=Cc1cc(c(cc1n2cc(nc2)C3CC3)C(=O)Nc4cccc(n4)c5nncn5C(C)C)F
InChiKey=YIDDLAAKOYYGJG-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"GS-4997
Selonsertib",,
Selumetinib,nan,3,Astrazeneca,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'3EW',4u7z,3,0,456,3.5,88.4,6,3,6,nan,"MAP2K1
MAP2K2",STE,"Smiles=Cn1cnc2c1cc(c(c2F)Nc3ccc(cc3Cl)Br)C(=O)NOCCO
InChiKey=CYOHGALHFOKKQC-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"ARRY-142886
AZD-6244
ARRY-886
Selumetinib",,
Semaxanib,nan,3,Sugen,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'X2M',2x2m,1,0,238.1,3.1,44.9,1,2,1,Investigated for use/treatment in colorectal cancer and lung cancer.,KDR,Tyr,"Smiles=Cc1cc([nH]c1/C=C\2/c3ccccc3NC2=O)C
InChiKey=WUWDLXZGHZSWQZ-WQLSENKSSA-N",nan,nan,Achiral Molecule,"SU-5416
Semaxinib
Semaxanib",,
Silmitasertib,nan,2,Senhwa Biosciences,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'3NG',3nga 3pe1 5o11 6fyl 6fyp 6fyv 6hmb 6isj 6k3l 6khd 6khe 6khf 6p5s,1,0,349.1,4.9,75.1,4,2,3,nan,"CSNK2A1
CSNK2A2",Other,"Smiles=c1cc(cc(c1)Cl)Nc2c3ccncc3c4ccc(cc4n2)C(=O)O
InChiKey=MUOKSQABCJCOPU-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Silmitasertib
CX-4945",,
Simotinib,nan,3,Advenchen Laboratories,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,1,500.2,4.4,78,8,1,7,nan,EGFR,Tyr,"Smiles=COc1cc2c(cc1OCCN3CC4(CC4)C5(C3)OCCO5)c(ncn2)Nc6ccc(c(c6)Cl)F
InChiKey=OXWUWXCJDBRCCG-UHFFFAOYSA-N",nan,nan,nan,SIM-6802,,
Sitravatinib,nan,3,Mirati Therapeutics,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,2,629.2,6.5,114.5,8,3,12,nan,"RET
DDR2
NTRK1
NTRK2
NTRK3",Tyr,"Smiles=COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=O)C5(CC5)C(=O)Nc6ccc(cc6)F
InChiKey=WLAVZAAODLTUSW-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MGCD516
Sitravatinib",,
Solcitinib,nan,2,GlaxoSmithKline,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,389.2,3.2,79.6,5,1,4,nan,JAK1,Tyr,"Smiles=CC1(CN(C1)C(=O)c2ccc(cc2)c3cccc4n3nc(n4)NC(=O)C5CC5)C
InChiKey=MPYACSQFXVMWNO-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"GLPG-0788
GSK2586184A
Solcitinib
GSK2586184
G-154578
GLPG-0778",,
Sonolisib,nan,2,Cascadian Therapeutics,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,1,525.2,3.1,119.4,9,1,8,nan,"PIK3CA
PIK3CB
PIK3CG",Atypical,"Smiles=CC(=O)O[C@@H]1C[C@]2([C@@H](CCC2=O)C3=C1[C@]4([C@H](OC(=O)/C(=C/N(CC=C)CC=C)/C4=C(C3=O)O)COC)C)C
InChiKey=QIUASFSNWYMDFS-NILGECQDSA-N",nan,nan,Single Stereoisomer,"Sonolisib
PX-866",,
Sorafenib,Nexavar,4,Bayer,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'BAX',1uwh 1uwj 3gcs 3heg 3rgf 3wze 4asd 5hi2,2,1,464.1,5.5,92.3,4,3,5,Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.,"BRAF
RAF1
FLT4
KDR
FLT3
PDGFRB
KIT
FGFR1
RET
FLT1","TKL
Tyr","Smiles=CNC(=O)c1cc(ccn1)Oc2ccc(cc2)NC(=O)Nc3ccc(c(c3)C(F)(F)F)Cl
InChiKey=MLDQJTXFUGDVEO-UHFFFAOYSA-N",2005,US-7235576-B1,Achiral Molecule,"Nexavar
Sorafenib
BAY-43-9006",Y,205.6
Sotrastaurin,nan,2,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'LW4',3iw4,nan,0,438.2,2.4,94.2,6,2,3,nan,nan,,"Smiles=CN1CCN(CC1)c2nc3ccccc3c(n2)C4=C(C(=O)NC4=O)c5c[nH]c6c5cccc6
InChiKey=OAVGBZOFDPFGPJ-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"AEB-071
NVP-AEB071
AEB071
Sotrastaurin",,
Spebrutinib,nan,2,Celgene,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,423.2,4.3,97.4,7,3,10,nan,BTK,Tyr,"Smiles=COCCOc1ccc(cc1)Nc2ncc(c(n2)Nc3cccc(c3)NC(=O)C=C)F
InChiKey=KXBDTLQSDKGAEB-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"CC-292
AVL-292
Spebrutinib",,
Sunitinib,Sutent,4,Cp Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'B49',2y7j 3g0e 3g0f 3miy 3ti1 4agd 4ks8 4qmz 6nfy 6nfz 6ng0,1,0,398.2,3.3,77.2,3,3,7,For the treatment of advanced renal cell carcinoma as well as the treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate.,"PDGFRB
FLT1
KIT
KDR
FLT4
FLT3
CSF1R
PDGFRA",Tyr,"Smiles=CCN(CC)CCNC(=O)c1c(c([nH]c1C)/C=C\2/c3cc(ccc3NC2=O)F)C
InChiKey=WINHZLLDWRZWRT-ATVHPVEESA-N",2006,US-6573293-B2,Achiral Molecule,"Sutent
Sunitinib
SU-11248
Sutent",Y,
Tafetinib,nan,1,Nanjing Yoko Biomedical,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,424.2,3.7,77.2,3,3,6,nan,"KDR
FLT4
FLT1",Tyr,"Smiles=CCN(CC)CCNC(=O)c1c([nH]c\2c1CCC/C2=C/3\c4cc(ccc4NC3=O)F)C
InChiKey=KGSRYTUWXUESJK-FXBPSFAMSA-N",nan,nan,nan,,,
Talmapimod,nan,2,Scios inc,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'469',3hub 3zsh,1,1,512.2,4,65.9,5,0,5,Investigated for use/treatment in pain (acute or chronic) and rheumatoid arthritis.,MAPK14,CMGC,"Smiles=C[C@@H]1CN([C@H](CN1C(=O)c2cc3c(cc2Cl)n(cc3C(=O)C(=O)N(C)C)C)C)Cc4ccc(cc4)F
InChiKey=ZMELOYOKMZBMRB-DLBZAZTESA-N",nan,nan,Single Stereoisomer,"Talmapimod
SCIO-469",,
Tamatinib,nan,2,Rigel Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'585',3fqs 3piy,1,0,470.2,3.6,128.8,10,3,7,nan,SYK,Tyr,"Smiles=CC1(C(=O)Nc2c(ccc(n2)Nc3c(cnc(n3)Nc4cc(c(c(c4)OC)OC)OC)F)O1)C
InChiKey=NHHQJBCNYHBUSI-UHFFFAOYSA-N",nan,nan,nan,R-406,,
Tandutinib,nan,2,Takeda,"ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,2,562.3,5,92.3,8,1,10,Investigated for use/treatment in leukemia (myeloid).,"FLT3
PDGFD","(*)
Tyr","Smiles=CC(C)Oc1ccc(cc1)NC(=O)N2CCN(CC2)c3c4cc(c(cc4ncn3)OCCCN5CCCCC5)OC
InChiKey=UXXQOJXBIDBUAC-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Tandutinib
MLN-0518
CT-53518
MLN-518",,
Tanzisertib,nan,2,Celgene,"ChemSpider
ChEMBL
DrugBank
RCSB
PDBe
ZINC
FDA SRS
BindingDB",'KBI',3tti,1,0,448.2,3.7,97.1,8,3,5,nan,MAPK8,CMGC,"Smiles=c1c(c(c(cc1F)F)Nc2n(c3nc(ncc3n2)N[C@H]4CC[C@@H](CC4)O)[C@@H]5COCC5)F
InChiKey=IBGLGMOPHJQDJB-IHRRRGAJSA-N",nan,nan,Single Stereoisomer,"Tanzisertib
JNK-930
CC-930",,
Tarloxotinib,nan,2,Threshold Pharmaceuticals,"ChemSpider
PubChem
FDA SRS",NaN,NaN,nan,1,679,1.6,140.8,9,2,9,nan,EGFR,Tyr,"Smiles=Cn1cnc(c1C[N+](C)(C)C/C=C/C(=O)Nc2cc3c(cn2)ncnc3Nc4ccc(c(c4)Br)Cl)[N+](=O)[O-].[Br-]
InChiKey=WAKIMVYUBWMMHJ-FXRZFVDSSA-N",nan,nan,nan,,,
Taselisib,nan,3,Hoffmann-La Roche,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'799',5t8f,1,0,460.2,3.2,118.7,9,1,5,nan,"PIK3CA
PIK3CD
PIK3CG",Atypical,"Smiles=Cc1nc(n(n1)C(C)C)c2cn3c(n2)-c4ccc(cc4OCC3)c5cnn(c5)C(C)(C)C(=O)N
InChiKey=BEUQXVWXFDOSAQ-UHFFFAOYSA-N",nan,nan,Racemic Mixture,"RG-7604
Taselisib
GDC-0032",,
Telatinib,nan,2,Bayer,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,409.1,4,102.2,7,2,6,nan,"KDR
FLT4",Tyr,"Smiles=CNC(=O)c1cc(ccn1)COc2c3c(cco3)c(nn2)Nc4ccc(cc4)Cl
InChiKey=QFCXANHHBCGMAS-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"BAY-57-9352
Telatinib
BAY-579352",,
Tepotinib,nan,2,Merck,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'3E8',4r1v,1,0,492.2,4,96.9,8,0,7,nan,MET,Tyr,"Smiles=CN1CCC(CC1)COc2cnc(nc2)c3cccc(c3)Cn4c(=O)ccc(n4)c5cccc(c5)C#N
InChiKey=AHYMHWXQRWRBKT-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"MSC-2156119
Tepotinib
MSC-2156119J
EMD-1214063",,
Tesevatinib,nan,2,Kadmon Corporation,"ChemSpider
ChEMBL
DrugBank
ZINC
FDA SRS",NaN,NaN,nan,1,490.1,5.8,59.5,6,1,6,nan,"EGFR
ERBB2
KDR
FLT4
EPHB4",Tyr,"Smiles=CN1C[C@H]2C[C@H](C[C@H]2C1)COc3cc4c(cc3OC)c(ncn4)Nc5ccc(c(c5F)Cl)Cl
InChiKey=HVXKQKFEHMGHSL-QKDCVEJESA-N",nan,nan,Racemic Mixture,"Tesevatinib
XL-647
KD-020
KD-019",,
Tivantinib,nan,3,Daiichi Sankyo,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'TIV',5cb4,nan,0,369.1,3.6,66.9,3,2,2,nan,MET,Tyr,"Smiles=c1ccc2c(c1)c(c[nH]2)[C@H]3[C@@H](C(=O)NC3=O)c4cn5c6c4cccc6CCC5
InChiKey=UCEQXRCJXIVODC-PMACEKPBSA-N",nan,nan,Single Stereoisomer,"ARQ-197
Tivantinib",,
Tivozanib,nan,4,Aveo Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'AV9',4ase,2,1,454.1,5.6,107.7,7,2,6,Tivozanib is an oral VEGF receptor tyrosine kinase inhibitor.,"FLT1
KDR
FLT4",Tyr,"Smiles=Cc1cc(no1)NC(=O)Nc2ccc(cc2Cl)Oc3ccnc4c3cc(c(c4)OC)OC
InChiKey=SPMVMDHWKHCIDT-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"AV-951
Tivozanib
Kil-8951
Kil8951
ASP-4130
KRN-951",N,
Toceranib,nan,0,Pfizer,"ChemSpider
ChEMBL
PubChem
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,396.2,3.1,77.2,3,3,5,nan,KIT,KIT,"Smiles=Cc1c([nH]c(c1C(=O)NCCN2CCCC2)C)/C=C\3/c4cc(ccc4NC3=O)F
InChiKey=SRSGVKWWVXWSJT-ATVHPVEESA-N",nan,nan,Achiral Molecule,"PHA-291639
Toceranib",,
Tofacitinib,Xeljanz,4,Pfizer,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'MI1',3eyg 3fup 3lxk 3lxn 4oti,1,0,312.2,1.5,88.9,5,1,3,"For the treatment of moderate to severe rheumatoid arthritis which is resistant or intolerant to methotrexate therapy. It may also be used as an adjunct to methotrexate therapy, or other non-biologic disease-modifying antirheumatic drugs (DMARDS), when methotrexate alone is not sufficient. Tofacitinib has also been investigated as a preventative therapy for kidney transplant rejections, and as a treatment for psoriasis, ulcerative colitis, and ankylosing spondylitis. It is not to be initiated in patients with a history of chronic or recurrent infections, or in the presence of active infection, even if localized, due to reports of serious and sometimes fatal infections (commonly pneumonia, herpes zoster and urinary tract infections). Use of tofacitinib is also discouraged in those who have been, or are likely to be, exposed to TB. An increased likelihood of exposure may be encountered by traveling to certain areas. In addition, tofacitinib is not to be used in patients with severe hepatic impairment, or low hemoglobin (less than 9g/dL). Cautioned is advised when using tofacitinib in patients at risk of gastrointestinal perforation, and in the elderly who are more susceptible to infection.","JAK1
JAK2
JAK3
TYK2",Tyr,"Smiles=C[C@@H]1CCN(C[C@@H]1N(C)c2c3cc[nH]c3ncn2)C(=O)CC#N
InChiKey=UJLAWZDWDVHWOW-YPMHNXCESA-N",2012,US-6956041-B2,Single Stereoisomer,"Tasocitinib
550
CP-690550
CP-690
Tofacitinib",Y,
Tomivosertib,nan,2,Effector Therapeutics,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS",'N45',6ck6,nan,0,340.2,1.6,114.9,7,3,2,"Tomivosertib, also known as eFT508 is a MNK1/2 inhibitor. Tomivosertib binds to and inhibits the activity of MNK1 and 2. This prevents MNK1/2-mediated signaling, and inhibits the phosphorylation of certain regulatory proteins, including eukaryotic translation initiation factor 4E (eIF4E), that regulate the translation of messenger RNAs (mRNAs) involved in tumor cell proliferation, angiogenesis, survival and immune signaling",nan,,"Smiles=Cc1cc(c(=O)n2c1C(=O)NC23CCCCC3)Nc4cc(ncn4)N
InChiKey=HKTBYUWLRDZAJK-UHFFFAOYSA-N",nan,nan,nan,NK1 AND MNK2,,
Tozasertib,nan,2,Merck,"ChemSpider
ChEMBL
PubChem
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'VX6',2f4j 2xyn 3amb 3e5a 4af3 4b8m 4jbq 4zog 5wnm 6brj 6gr9,1,0,464.2,3.5,102.1,8,3,7,nan,"AURKA
AURKB
AURKC",Other,"Smiles=Cc1cc(n[nH]1)Nc2cc(nc(n2)Sc3ccc(cc3)NC(=O)C4CC4)N5CCN(CC5)C
InChiKey=GCIKSSRWRFVXBI-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"VX-680
MK-0457
Tozasertib
VX-68
MK-045",,
Trametinib,Mekinist,4,GlaxoSmithKline,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,3,1,615.1,3.9,107.1,8,2,5,"Trametinib is indicated for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.","BRAF
MAP2K1
MAP2K2","TKL
STE","Smiles=Cc1c2c(c(n(c1=O)C)Nc3ccc(cc3F)I)c(=O)n(c(=O)n2c4cccc(c4)NC(=O)C)C5CC5
InChiKey=LIRYPHYGHXZJBZ-UHFFFAOYSA-N",2013,US-7378423-B2,Achiral Molecule,"Mekinist
GSK1120212
Trametinib",Y,293-303
Trilaciclib,nan,2,G1 Therapeutics,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,446.3,2.7,91.2,8,2,3,nan,"CDK4
CDK6",CMGC,"Smiles=CN1CCN(CC1)c2ccc(nc2)Nc3ncc4cc5n(c4n3)C6(CCCCC6)CNC5=O
InChiKey=PDGKHKMBHVFCMG-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"G1T28
Trilaciclib",,
Tucatinib,nan,2,Array BioPharma,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,1,480.2,5.1,110.9,10,2,5,nan,ERBB2,Tyr,"Smiles=Cc1cc(ccc1Oc2ccn3c(c2)ncn3)Nc4c5cc(ccc5ncn4)NC6=NC(CO6)(C)C
InChiKey=SDEAXTCZPQIFQM-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"Tucatinib
ONT-380
ARRY-380",,
Ulixertinib,nan,2,BioMed Valley Discoveries,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS",'EVK',6gdq,nan,0,432.1,4.7,90,4,4,7,nan,"MAPK1
MAPK3",CMGC,"Smiles=CC(C)Nc1cc(c(cn1)Cl)c2cc([nH]c2)C(=O)N[C@H](CO)c3cccc(c3)Cl
InChiKey=KSERXGMCDHOLSS-LJQANCHMSA-N",nan,nan,Single Stereoisomer,"VRT752271
VRT-752271
BVD-523",,
Umbralisib,nan,3,TG Therapeutics,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,2,571.2,6.7,109.1,8,1,6,nan,nan,,"Smiles=C[C@@H](c1c(c(=O)c2cc(ccc2o1)F)c3cccc(c3)F)n4c5c(c(n4)c6ccc(c(c6)F)OC(C)C)c(ncn5)N
InChiKey=IUVCFHHAEHNCFT-INIZCTEOSA-N",nan,nan,Single Stereoisomer,"Umbralisib
TGR-1202 base
RP-5264",,
Upadacitinib,Rinvoq,4,Abbvie,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS",NaN,NaN,nan,0,380.2,2.9,78.3,4,2,3,"On august 2019, FDA approved fedratinib to treat adults with moderately to severely active rheumatoid arthritis",JAK1,Tyr,"Smiles=CC[C@@H]1CN(C[C@@H]1c2cnc3n2c4cc[nH]c4nc3)C(=O)NCC(F)(F)F
InChiKey=WYQFJHHDOKWSHR-MNOVXSKESA-N",2019,nan,Single Stereoisomer,"ABT-494
Upadacitinib",Y,
Uprosertib,nan,2,GlaxoSmithKline,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,428.1,3.6,86.1,5,2,6,nan,"AKT1
AKT2
AKT3",AGC,"Smiles=Cn1c(c(cn1)Cl)c2cc(oc2Cl)C(=O)N[C@@H](Cc3ccc(c(c3)F)F)CN
InChiKey=AXTAPYRUEKNRBA-JTQLQIEISA-N",nan,nan,Single Stereoisomer,"Uprosertib
GSK2141795C
GSK2141795",,
Vactosertib,nan,1.5,MedPacto,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,399.2,4.2,83.8,6,2,5,"Vactosertib (EW-7197) acts as in inhibitor of transforming growth factor beta receptor 1B (ALK5) and activin A receptor type IB (ALK4). The compound is potent, selective, and orally bioavailable, and exhibits experimental anti-tumour activity.",nan,,"Smiles=Cc1cccc(n1)c2c(nc([nH]2)CNc3ccccc3F)c4ccc5ncnn5c4
InChiKey=FJCDSQATIJKQKA-UHFFFAOYSA-N",nan,nan,nan,,,
Vandetanib,Caprelsa;Zactima,4,Ipr Pharmaceuticals,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'ZD6',2ivu,1.5,1,474.1,5,59.5,6,1,6,"Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.","VEGFA
EGFR
PTK6
TEK
RET","(*)
Tyr","Smiles=CN1CCC(CC1)COc2cc3c(cc2OC)c(ncn3)Nc4ccc(cc4F)Br
InChiKey=UHTHHESEBZOYNR-UHFFFAOYSA-N",2011,US-RE42353-E1,Achiral Molecule,"Caprelsa;Zactima
GNF-Pf-2188
ZD-6474
Vandetanib
ZD-64",Y,
Varlitinib,nan,2.5,Array Biopharma,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,466.1,5.2,93.5,9,2,6,Investigated for use/treatment in cancer/tumors (unspecified).,"EGFR
ERBB2",Tyr,"Smiles=C[C@@H]1COC(=N1)Nc2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5nccs5
InChiKey=UWXSAYUXVSFDBQ-CYBMUJFWSA-N",nan,nan,Single Stereoisomer,"ARRY-543
ASLAN-001
Varlitinib
ARRY-334543",,
Vatalanib,nan,3,Novartis,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,1,346.1,5,50.7,4,1,4,Used in combination with first- and second-line chemotherapy for the treatment of metastatic colorectal cancer and non-small cell lung cancer (NSCLC).,"FLT1
KDR
FLT4",Tyr,"Smiles=c1ccc2c(c1)c(nnc2Nc3ccc(cc3)Cl)Cc4ccncc4
InChiKey=YCOYDOIWSSHVCK-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"BAY-86-5127
PTK-787
NVP-PTK787
ZK-222584
K-222584
CGP-79787
PTK787
Vatalanib",,
Vemurafenib,Zelboraf,4,Hoffmann-La Roche,"ChemSpider
ChEMBL
PubChem
DrugBank
RCSB
PDBe
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",'032',3og7 4rzv 5hes,1.5,1,489.1,5.5,91.9,4,2,7,"Vemurafenib is approved since 2011 for the treatment of metastatic melanoma with a mutation on BRAF in the valine located in the exon 15 at codon 600, this mutation is denominated as V600E.",BRAF,TKL,"Smiles=CCCS(=O)(=O)Nc1ccc(c(c1F)C(=O)c2c[nH]c3c2cc(cn3)c4ccc(cc4)Cl)F
InChiKey=GPXBXXGIAQBQNI-UHFFFAOYSA-N",2011,US-7504509-B2,Achiral Molecule,"Zelboraf
Vemurafenib
PLX-4032
Ro-5185426
RG-7204",Y,272
Verosudil,nan,2,Aerie Pharmaceutical,"ChemSpider
ChEMBL
PubChem
Guide to Pharmacology",NaN,NaN,nan,0,327.1,2.8,65.2,4,2,4,nan,nan,,"Smiles=CN(C)C(c1ccsc1)C(=O)Nc2ccc3c(c2)cc[nH]c3=O
InChiKey=VDYRZXYYQMMFJW-UHFFFAOYSA-N",nan,nan,Racemic Mixture,"Verosudil
AR-12286",,
Vistusertib,nan,2,Astrazeneca,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,462.2,2.5,92.7,8,1,4,nan,MTOR,Atypical,"Smiles=C[C@H]1COCCN1c2c3ccc(nc3nc(n2)N4CCOC[C@@H]4C)c5cccc(c5)C(=O)NC
InChiKey=JUSFANSTBFGBAF-IRXDYDNUSA-N",nan,nan,Single Stereoisomer,"AZD-2014
AZD2014
Vistusertib",,
Volasertib,nan,3,Boehringer Ingelheim,"ChemSpider
ChEMBL
DrugBank
RCSB
PDBe
Guide to Pharmacology
FDA SRS
BindingDB",'IBI',3fc2 5v67 5vbr,1,1,618.4,4.3,106.2,9,2,10,nan,PLK1,Other,"Smiles=CC[C@H]1N(c2nc(ncc2N(C1=O)C)Nc3c(cc(cc3)C(=O)N[C@H]4CC[C@@H](CC4)N5CCN(CC5)CC6CC6)OC)C(C)C
InChiKey=SXNJFOWDRLKDSF-STROYTFGSA-N",nan,nan,Single Stereoisomer,"BI-6727
Volasertib",,
Voruciclib,nan,2,Piramal Enterprises,"ChemSpider
ChEMBL
PubChem
DrugBank
Guide to Pharmacology
ZINC
FDA SRS
BindingDB",NaN,NaN,nan,0,469.1,4.3,94.1,6,3,3,nan,CDK4,CMGC,"Smiles=CN1CC[C@H]([C@@H]1CO)c2c(cc(c3c2oc(cc3=O)c4ccc(cc4Cl)C(F)(F)F)O)O
InChiKey=MRPGRAKIAJJGMM-OCCSQVGLSA-N",nan,nan,Single Stereoisomer,,,
Voxtalisib,nan,2,Sanofi,"ChemSpider
ChEMBL
PubChem
DrugBank
ZINC
FDA SRS",NaN,NaN,nan,0,270.1,1.1,102.5,6,2,2,nan,"PIK3CA
MTOR",Atypical,"Smiles=CCn1c2c(cc(c1=O)c3ccn[nH]3)c(nc(n2)N)C
InChiKey=RGHYDLZMTYDBDT-UHFFFAOYSA-N",nan,nan,Achiral Molecule,"SAR-245409
Voxtalisib
XL-765",,
Zanubrutinib,nan,4,BeiGene,"ChemSpider
ChEMBL
PubChem
BindingDB",NaN,NaN,nan,0,471.2,4.2,102.5,6,2,6,"Zanubrutinib (BGB-3111) is a potent, selective and and irreversible BTK inhibitor that is being investigated for clinical utility in the treatment of hematological cancers, such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL) [1-2].",nan,,"Smiles=C=CC(=O)N1CCC(CC1)C2CCNc3n2nc(c3C(=O)N)c4ccc(cc4)Oc5ccccc5
InChiKey=RNOAOAWBMHREKO-UHFFFAOYSA-N",2019,nan,nan,"BGB-3111
ZANUBRUTINIB",Y,
